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Retinoic acid (RA) is thought to signal through retinoic acid receptors (RARs), i.e. 
RARα, β, and γ to play important roles in embryonic development and tissue regeneration. In 
this thesis, the zebrafish (Danio rario) was used as a vertebrate model organism to examine the 
role of RARγ. Treatment of zebrafish embryos with a RARγ specific agonist reduced the axial 
length of developing embryos, associated with reduced somite number and loss of hoxb13a 
expression. There were no clear alterations in hoxc11a or myoD expression. Treatment with the 
RARγ agonist disrupted the formation of anterior structures of the head, the cranial bones and 
the anterior lateral line ganglia, associated with a loss of sox9 immunopositive cells in the same 
regions. Pectoral fin outgrowth was blocked by treatment with the RARγ agonist; however, this 
was not associated with loss of tbx5a immunopositive lateral plate cells and was reversed by 
wash out of the RARγ agonist or co-treatment with a RARγ antagonist. Regeneration of the 
transected caudal fin was also blocked by RARγ agonist treatment and restored by agonist 
washout or antagonist co-treatment; this phenotype was associated with a localised reduction in 
canonical Wnt signalling. Conversely, elevated canonical Wnt signalling after RARγ treatment 
was seen in other tissues, including ectopically in the notochord. Furthermore, some phenotypes 
seen in the RARγ treated embryos were present in mutant zebrafish embryos in which canonical 
Wnt signalling was constitutively increased. These data suggest that RARγ plays an essential 
role in maintaining neural crest and mesodermal stem/progenitor cells during normal embryonic 
development and tissue regeneration when the receptor is in its non-ligated state. In addition, 
this work has provided evidence that the activation status of RARγ may regulate hoxb13a gene 
expression and canonical Wnt signalling. Further research is required to confirm such novel 
regulatory roles. 
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Chapter 1 
 Introduction 
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1.1. Retinoic Acid 
Retinoic acid (RA) is an active metabolite derived from vitamin A. Its role in medicine 
and biology has been the subject of interest since the early age of ancient civilization.  More and 
more discoveries about RA and its functions were made throughout the centuries of scientific 
research alongside with the evolution of scientific awareness and improved technology. RA 
functions have been involved in many essential biological processes during life, especially 
including developmental biology, stem cells and regeneration. Therefore, RA is considered one 
of the most important molecules in the biology, involved in the regulations of many tasks.  
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1.2. Discovery of RA 
Retina was first discovered and named as retinol by a German mathematician and 
astronomer called Johannes Kepler (Finger 2001). The name of retinol, derived from its 
involvement in retinal biology, which is a part of the eye. In fact, retina came from the Latin 
word “rete” which means the net of eye.                                 
The structure of vitamin A was first proposed by Paul Karrer, in 1952 (D’Ambrosio et 
al., 2011), who also showed its roles in the retina, although the discovery of vitamin A was in 
the 1920s. There were several studies which ran from the 1930s to 1950s leading to the 
identification of different isoforms of vitamin A, but Dowling and Wald (1960) finally called 
one of the isoform as vitamin A acid, because it has the carboxylic acid group instead of 
hydroxyl group.  Another paper published in the same year also mentioned the effects of 
hypervitaminosis A was due to vitamin A acid (Thompson and Pitt 1960). One year later, it was 
shown that vitamin A acid was oxidized enzymatically from vitamin A aldehyde (Futterman 
1961). Therefore, multiple events from the studies of the retina and eye disease through to the 
discovery of vitamin A led to the discovery of RA. 
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1.3. Chemical structures and properties of RA 
Vitamin A (retinol) and RA share similar chemical structures (Figure 1.1). Both have 
four isoprenoid units attached to the cyclic ring, although retinol has a hydroxyl group attached 
to the end of the polyunsaturated side chain whereas the carboxylic group is attached to RA. In 
fact, RA is not the only derivatives of retinol. The two other metabolites of retinol are 9-cis-RA 
and 11-cis-retinal, in which the roles of the former are less known while the roles of the latter is 
well known in vision are understood better (Blomhoff and Blomhoff 2006).  Among the 
metabolites of RA, all-trans-RA is the most common form found in in vivo (Blomhoff and 
Blomhoff 2006). Therefore, in this thesis, the abbreviation RA has been used to refer to all-
trans-RA rather than 9-cis-retinoic acid.  
In fact, all the retinol derivatives and retinol share similar chemical structures and 
carbon numbers, although individual derivatives have different groups attached to the side 
chain, as well as trans and cis isomeric forms. Therefore, the International Union of Pure and 
Applied Chemistry (IUPAC) designated the term “ retinoid”, which applies to all of chemical 
compounds consisting of four isoprenoid units joined in a head-to-tail manner between a 
monocyclic parent compound at one end and a functional terminal group at the other (Johnson 
1994). It is generally assumed that the natural or synthetic compounds which share the similar 
chemical structures and biological functions are called “retinoid” by definition. However, some 
synthetic chemicals produce similar biological responses similar to the retinoid responses 
regardless to their different chemical structure.  Therefore, the term “retinoid” nowadays refer 
to all the compounds which have similar chemical structures plus the synthetic compounds 
which produce the similar biological activities regardless to their structures (Johnson 1994).  
 All retinoid are very sensitive to oxygen and light (Blomhoff and Blomhoff 2006). 
Moreover, the presence of a polyunsaturated chain provides hydrophobic properties to retinols 
(Curley 2012). Therefore, vitamin A itself is one of the fat soluble vitamins, alongside vitamins 
D, E and K. In in vivo, the trans form of RA is the most common form found in the body, 
15 
 
whereas 11-cis-retinal is strictly found in the retina (Blomhoff and Blomhoff 2006). Therefore, 
the roles of atRA in vivo are well known compared to the 9-cis-RA. However, a recent paper 
has reported that 9-cis-RA was found in murine pancreatic cells although its roles in pancreas 
are still not clear (Kane et al., 2010). 
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Retinol (Vitamin A) 
All-trans-Retinoic Acid (AtRA) 
9-cis-Retinoic Acid 11-cis-Retinal 
 
Figure 1.1. Structures of vitamin A and its derivatives, all-trans RA, 9-cis RA and 11-cis 
retinal 
The chemical structures of vitamin A and its metabolites are explained. Vitamin A and all its 
derivatives are composed of three main chemical groups, a cyclic ring, a polyunsaturated chain 
and a terminal group. The different forms are decided by substituting the terminal group at the 
end of the polyunsaturated chain. For example, the hydroxyl group (blue circled) is attached to 
the vitamin A, retinol while the carboxylic acid and aldehyde groups (red circles) are attached 
to the RA and 11-cis retinal respectively. RA also exists as all-trans and 9-cis forms although 
the main active found in in vivo is all-trans form.  
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1.4. Sources of RA 
RA is synthesized by a series of enzymatic reactions from vitamin A (Theodosiou et al., 
2010). Vitamin A cannot be synthesized within the animal bodies. Therefore, the only source of 
vitamin A is dietary. Although animals have to rely on the dietary vitamin A, plants and 
microorganisms have the ability to synthesize it by themselves. The precursors of vitamin A are 
known as carotenoids and are rich in yellow, orange, red and purple colour plants, fruits and 
vegetables (Fraser and Bramley 2004). The carotenoids are cleaved into vitamin A in the liver 
of animals (D’Ambrosio et al., 2011). Therefore, the two main sources of vitamin A in the diet 
are carotenoid-rich vegetables and animal liver, which already has vitamin A (Blomhoff and 
Blomhoff 2006). A summary of dietary vitamin A intake and processing has been summarized 
in D’Ambrosio et al., (2011). The structure of vitamin A consists of a β-ionone ring, a 
polyunsaturated side chain and a polar end group, making the molecule more hydrophobic and 
lipophilic (Figure 1.1) (Curley 2012). Dietary vitamin A, retinol, is absorbed by the enterocyte 
of the small intestine alongside other dietary fats. Retinol is then transformed into retinyl ester 
by lecithin:retinol acyltransferase (LRAT) in the intestinal enterocyte. Retinyl ester is packed 
into chylomicrons alongside other dietary fat and cholesterol and is secreted into the lymphatic 
system to transport them to the liver. The chylomicrons are picked up by the liver hepatocytes. 
The retinyl ester is hydrolysed back to retinol by the hepatic retinyl ester hydrolases (REHs) in 
the hepatocyte. Retinol is bound to retinol binding protein (RBP) and secreted into the 
bloodstream for peripheral distribution (Figure 1.2). 
RA is an important morphogen for embryonic development and is involved in various 
developmental processes. Maternal retinol is transferred to the zygote because retinol cannot be 
synthesized within the zygote. The transfer process of retinol from the adult to the embryo is 
summarized in Rhinn and Dollé (2012). Retinol binding protein 4(RBP4) is the main protein 
bound to retinol in the mammalian blood stream, because the carrier proteins are required for 
the hydrophobic retinol distribution. In mammals, the retinol is transferred from mother to the 
embryo via the placenta. In oviparous species, in which a yolk sac is attached to the embryo, the 
18 
 
circulating retinol is accumulated from the blood stream into the yolk sac during vitellogenesis 
or yolk sac deposition. Therefore, the yolk sac serves as the main source of vitamin A for 
oviparous embryos. However, maternal RBP4 itself cannot cross the placenta or yolk sac. 
Therefore, retinol diffuses across the placenta and yolk sac membrane and is picked up by the 
zygotic RBP on the embryo side. At the target cells, the RBP bound retinol is taken by into the 
cytoplasm via STRA6 (stimulated by retinoic acid) transmembrane protein (Kawaguchi et al., 
2007).    
 
  
19 
 
 
                             
LRAT
Enterocyte
Dietary retinol
retinol retinyl ester
retinyl ester retinol
Liver
REH
Embryoretinol retinaldehyde
RBP4+STRA6
ADH
RADLH
Retinoic acid
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Figure 1.2. Flow diagram of RA metabolism including its source, transport, synthesis and 
degradation. 
RA metabolism starts from the diet. Dietary vitamin A (retinol) is absorbed in the intestine 
where it is transformed into retinyl ester by lecithin:retinyl acyl-transferase (LRAT). Retinyl 
ester is transported to the liver via the bloodstream, where it is stored as retinol. Peripheral 
distribution is carried out by the retinol binding protein synthesized (RBP4) by liver. At the 
targeted cells, retinol is synthesized into RA by two step reactions, from retinol to retinaldehyde 
by alcohol dehydrogenase (ADH) and from retinaldehyde to RA by retinaldehyde 
dehydrogenase (RALDH). Excess RA is degraded by the cyp26 enzyme into 4-hydroxy RA 
which is non-active form.  
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1.5. RA Synthesis 
Vitamin A is transformed into two main metabolites inside the body, known as all-
trans-retinoic acid (RA) and 11-cis-retinal (Blomhoff and Blomhoff 2006). 11-cis-retinal plays 
in an important role in vision. It binds to the opsins of the retina which are light sensors which 
involve in the visual cycle (Kusakabe et al., 2009). The active form of RA inside the body is all 
trans. RA is synthesized by two step reactions from retinol in the cytoplasm. The first step of 
retinoic acid biosynthesis is oxidation of retinol to retinaldehyde. The enzyme involves in this 
oxidation process is alcohol dehydrogenase (ADH) and the reaction is considered as the rate 
limiting step because it is slow reaction (Parés et al., 2008). The product, retinaldehyde is 
reversible to retinol (Napoli 1986).  
The second step reaction is irreversible conversion of retinaldehyde to RA by 
retinaldehyde dehydrogenase (RALDH) (Duester 2008). There are four RALDHs which are 
discovered in vertebrates named as RALDH1, RALDH2, RALDH3 and RALDH4 (Albalat and 
Cañestro 2009). The synthesized RA is metabolically active and can travel across the cell 
membrane. Therefore, RA acts as a paracrine morphogen. Its regulation needs to be controlled 
tightly and the RA degradation is performed by the enzymes of cytochrome P26 family 
(CYP26) (Petkovich 2001) (Figure 1.2).  
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1.6. Conventional RA signalling 
RA is metabolically active and can function through its receptors at the targeted cells. 
Here, the term “conventional” is used for a particular well known RA signalling where it binds 
to the nuclear receptors which have high affinity to RA. These receptors are known as the 
retinoid acid receptors (RARs). RA can also bind to the non-conventional retinoic acid 
receptors (Theodosiou et al., 2010). The RARs belong to the nuclear receptor family, which has 
two main domains, DNA binding domain and ligand binding domain (Petkovich 2001). In fact, 
RARs interact with another type of nuclear receptor known as retinoid x receptor (RXR). In the 
nucleus, RAR and RXR forms a heterodimer and binds to the specific DNA sequence known as 
retinoic acid response element (RARE) (Mangelsdorf et al., 1990). There are three main RAR 
in vertebrates, known as α, β and γ (Lohnes et al., 1994).  The non-conventional RA signalling 
involves peroxisome proliferator-activated receptor gamma (PPARG) and retinoic acid receptor 
related orphan receptors (RORs) (Theodosiou et al., 2010).  
The details of RA signalling is explained in (Kam et al., 2012). In RA responsive cells, 
the ligand (RA) is translocated from the cytoplasm to the nucleus after binding to the cellular 
retinoic acid binding protein (CRABP). In the nucleus, RA binds to RAR/RXR heterodimer 
which is sitting on the RARE site together with co-repressor. Binding ligand to the receptor 
complex leads to the conformational changes of RAR/RXP complex followed by the release of 
co-repressor and recruitment of co-activator resulting in the gene transcriptions (Figure 1.3). 
There are over 500 reported genes which are regulated by RA signalling and at least 127 genes 
are the candidates for direct targets (Blomhoff and Blomhoff 2006).  
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Figure 1.3.Conventional RA signalling 
The picture is adapted from (Linney et al., 2001) and the permission to reuse this figure is 
obtained from the publisher (License Number: 3636071077483) . At the ligand-free state, 
RAR/RXR heterodimer complex is bound to the specific DNA sequence known as retinoic acid 
response element (RARE) together with histone de-acetylase 3 (HDAC3) and co-repressor. 
However, the direct protein-protein interaction between RAR/RXR and HDAC3 has not been 
reported. Upon the ligand binding to the receptor, the conformational changes of RAR/RXR 
heterodimer allow the replacement of co-repressor by co-activator and HDAC3 by histone 
acetylase (HA), resulting in the RA targeted gene transcription.  
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1.7. Non-conventional RA signalling 
 RA can also bind to fatty acid binding protein 5, (FABP5). FABP5 is a family member 
of intracellular lipid binding protein (iLBP), which is the same family member as CRABP (Tan 
et al., 2002). FABPs are generally known for their ability to bind the fatty acids in the 
cytoplasm and translocate FABP-fatty acid into the nucleus to bind the peroxisome proliferator 
activated proteins (PPARs) in adipocytes and keratinocytes, the similar process of RA-CRABP 
translocation and binding to RAR-RXR (Tan et al., 2002). RA is shown to have a high binding 
capacity of FABP5, followed by the nuclear translocation of FABP5 and highly selective 
interaction with PPARβ/δ rather than other PPAR subtypes (Schug et al., 2007). Therefore, 
non-conventional RA signalling via PPARs suggests the roles of RA signalling might be more 
complicated than before in the studies which are related to the adipogenesis and energy 
homeostasis. RA is also shown its binding affinity to the one of the RA receptor related orphan 
receptor, RORβ (Stehlin-Gaon et al., 2003). RORs are orphanage from nuclear family member 
because of their monomer conformation while all the other nuclear receptor members exist as 
dimers (Jetten et al., 2001). 
 All the RA signalling mentioned above occurs within in the nucleus. In fact, RA also 
has the extra-nuclear effects. Several studies have shown RA can rapidly and transiently 
activate the several kinase cascades (Al Tanoury et al., 2013). 
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1.8. Structures of RARs 
Three subtypes of RARs, α, β and γ, are encoded by the separated genes. Each subtype 
also has the two isoforms depending on their promoters, alternative splicing mechanism and 
variable N terminal regions. In in vivo, RAR/RXR heterodimer acts as signal transducer after 
binding to the RA ligand, in which RXRs also have three different subtypes α,β and γ (Germain 
et al., 2006). Each of RARs has  a variable N-terminal domain (NTD), a conserved DNA 
binding domain (DBD) and a conserved ligand binding domain (LBD) (Al Tanoury et al., 2013) 
(Figure 1.4). DBD and LBD are connected by a flexible hinge peptide.  
 LDP is composed of 12 conserved α-helices and a β-turn, separated by loops and folded 
into three layers, helical sandwiches.  Helix number 12 (H12) has a conformational flexibility 
depending on the ligand free or bound stage. In addition, H12 conformational change is also 
involved in the heterodimerization with RXR as well as the interaction with multiple 
coregulators. The ligand, RA, binding pocket is made up of hydrophobic residues from the 
helices H3, H5 and H11 plus the β hair pin s1-s2. Heterodimerization surface is mainly 
composed of helices H9 and H10. 
 DBD consists of a sequence specific DNA binding region, which has two zinc-
nucleated modules and two α- helices. The DBD is made up of several highly conserved 
sequence elements, known as P,D,T and A boxes which are important for the dimerization as 
well as for the DNA sequence recognition.  
 Compared to the LBD and DBD, NTD is not conserved among the RARs, even among 
the isoforms. The structures of NTD are also naturally disordered according to the several 
biochemical and structural studies. Recent studies show NTDs have the regions which are 
reactive to the kinases and ubiquitin-ligases, suggesting the post-translational modification of 
NTD may play an important role for the specific functions of different RARs.                                
                                                       
26 
 
 
Figure 1.4. RAR Structure 
The picture is adapted from (Al Tanoury et al., 2013) and the permission to reuse this figure is 
obtained from the publisher (Reference Number- 240-283-6616). All the RARs have a 
conserved ligand binding domain (LBD), a conserved DNA binding domain (DBD), a hinge 
which connects LBD and DBD, and a variable N-terminal domain (NTD). The phosphorylation 
sites of the LBD and NTD are also shown. LBD possess a ligand binding pocket (red circle). 
DBD binds to the specific DNA sequence known as retinoic acid response element (RARE), 
which in turn acts as the transcriptional promoter for RA responsive genes.  
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1.9. Structure of PPARβ/δ 
 PPARs are also the member of nuclear receptor superfamily. Like RARs, PPARs forms 
the heterodimer with RXRs and also bind to RARE. There are three main subtypes of PPARs 
which are PPARα, PPARγ and PPARβ/δ. They are encoded by the separated genes but 
interestingly, they all share very similar structures to the RARs (Hihi et al., 2002). All the 
PPARs are sensitive to the various fatty acids and fatty acid derivatives. Interestingly, PPARβ/δ 
has the binding capacity to RA although its binding affinity to RA is lower than those of RARs. 
The binding pocket of PPARβ/δ is considering ably larger than any other nuclear receptor 
which may explain its binding affinity to RA (Xu et al., 1999).  
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1.10. Co-repressors, co-activators and co-regulators 
 In addition to the heterodimer formation with RXRs, RARs also interact with co-
repressors, co-activators and other co-regulators for gene regulations. These accessory proteins 
generally bind to the H3 and H4 hydrophobic areas of LBD (Glass and Rosenfeld 2000). 
Recently, other regulator proteins which bind to the NTD have been identified (Al Tanoury et 
al., 2013). Interestingly, RARβ and RARγ have poor interaction with co-repressors 
(Hauksdottir et al., 2003).  
 In ligand-bound stage, RARs recruit the co-activators. The known co-activators for 
RARα in ligand-bound stage are p160 family of steroid receptor co-activators (SRC), which are 
SRC1, SRC2 and SRC3 (Lefebvre et al., 1995).  
 In ligand free stage, RARs bind to the co-repressors. Nuclear receptor co-repressor 
(NCoR) and silencing mediator of retinoic acid and thyroid hormone (SMRT) are identified as 
the co-repressors of RARα (Al Tanoury et al., 2013). Unlike ligand free stage, ligand bound 
stage RARs recruit many molecules as the co-activators. These molecules are “Mediator” 
subunit (Lefebvre et al., 1995), the receptor interacting protein (RIP) (Hu et al., 2004), the 
preferentially expressed antigen in melanoma (PRAME) (Epping et al., 2005), the 
transcriptional intermediary factor-1α (TIF1α) (Le Douarin et al., 1995)and thyroid receptor 
interacting protein-1 (TRIP1) (vom Baur et al., 1996).  
There are many other molecules bound to LBD of RARs as co-regulators such as cyclin 
H (Bour et al., 2005) and CRABPII (Despouy et al., 2003). The molecules found in the NTD of 
RARs are Acinus-S, a nuclear protein involved in the apoptotic chromosome condensation and 
mRNA processing, and HACE1, and HECT domain and ankyrin repeat-containing E3 –
ubiquitin protein ligase (Vucetic et al., 2008; Zhao et al., 2009). 
29 
 
1.11. Retinoic acid response element (RARE) 
 RAR/RXR heterodimers bind to the specific sequence of DNA known as retinoic acid 
response element (RARE) and serves as the promoter of the target genes. RAREs are generally 
composed of two direct repeats (DR) of a core hexameric (A/G) G (G/T) TCA separated by 1,2 
or 5 nucleotides and referred as DR1, DR2 and DR5 (Balmer and Blomhoff 2005).  RAREs 
have been identified in the promoters of RA targets genes which have a variety of functions, 
such as transcription, cell signalling, development, neuronal functions and tumour suppression.   
 PPAR/RXR heterodimer also bind to the response element which has two direct repeats 
of a core hexameric motif with DR1 spacing and serves as a promoter for the genes involved in 
energy metabolism (Chandra et al., 2008). 
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1.12. Roles of RA during development 
           RA is a critical regulator for cell proliferation, cell differentiation, body axis formaton 
and organogenesis for a developing embryo (Mark et al., 2006). Different roles of RA have 
been reported in hindbrain formation,   pharyngeal arches and lungs formation, pancreatic 
formation, limb formation and somitogenesis.  
Experiments where excess RA is provided or RA is restricted in the developing embryo 
show changes in hindbrain pattern. Providing the excess vitamin A to the female pregnant rat 
causes  changes in the head morphology of embryo including hindbrain pattern changes 
(Morriss 1972). On the other hand, normal hindbrain development requires RA. When  
Japanese quails are provided with a vitamin A restricted diet, their embryos show severely 
truncated hindbrains (Gale et al., 1999). This hindbrain truncation can be rescued by injection 
of retinol into the egg, suggesting RA is needed for hindbrain formation (Gale et al., 1999). 
Similar changes are also found in the other vertebrates as well. The RA synthesizing enzyme, 
Raldh2 (-/-) knock- out mice shows lack of segmentation and reduction in posterior hindbrain 
(Niederreither et al., 2000). Zebrafish raldh2 mutant also shows the changes in  hindbrain 
pattern (Grandel et al., 2002; Begemann et al., 2001).  
Pharyngeal arches are the derivatives of neural crest cells and theese arches 
differentiate into a variety of tissues and organs including the cranial cartilages, parathyroid 
glands, thyroid gland and thymus. RA plays an important role for the formation of these tissues 
and organs during development. Raldh2(-/-) mice embryo dies from the cardiac defects and 
further investigation shows loss of pharyngeal arches in the mutant embryos (Niederreither 
2003). The genes affected in this mutant are Hoxa1 and Hoxb1, which are the downstream 
targets of retinoic acid responding element (RARE) (Niederreither 2003).  
Raldh2 (-/-) mutant mice shows a lack of primary lung bud induction and growth, the 
phenotype is also associated with increased level of TGF-beta signalling and decreased level of 
Fgf10 expression (Chen et al., 2010). Therefore, RA is crucial for lungs formation and growth.  
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RA is required for the induction of pancreatic primordia from endoderm by signalling 
from mesoderm. Zebrafish pancreatic mutant line shows mutations in aldh1a2 gene, which 
codes the enzyme to transform retinol to retinaldehyde. The chemical treatment with  aldh1a2 
inhibitor or morpholino blocking to aldh1a2 also show the defect in pancreas formation, 
confirming the important roles of RA in pancreas formation (Alexa et al., 2009). The similar 
pancreatic defect is also observed in the Raldh2(-/-) mice embryo (Molotkov et al., 2005).  
RA is also important for formation of forelimbs. Studies in zebrafish show RA 
necessary for induction of forelimb (Grandel and Brand 2011; Gibert et al., 2006). However, 
the growth of forelimb is independent of RA signalling. Studies of forelimb development in 
murine embryo show the growing limb expresses Cyp26b1 in the growing end of the limb and 
disruption of the gene results in outgrowth defect (Yashiro et al., 2004; Probst et al., 2011).  
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1.13. Functions of individual RAR during development 
 Although RA signalling is important for a variety of development, the roles of 
individual receptor are still not clear. Based on their pattern of expressions during development, 
the possible roles of individual RAR are summarized in (Dollé 2009) (Figure 1.6). The gene 
knock out experiments for individual receptor in mouse show RARα and β knock out embryos 
are viable and mild phenotypes (Li et al., 1993; Ghyselinck et al., 1997). However, RARγ 
knock out mice has severe growth defect including bone dysmorphogenesis (Subbarayan et al., 
1997). Therefore, it was generally thought RARγ has a very important role for normal 
embryonic development 
 Interestingly, the idea of “a binary ligand-dependent transcriptional repressor-activator 
paradigm for RAR function” has been proposed based on the in vitro studies (Bastien and 
Rochette-Egly 2004). The binary paradigm of RARs suggests the receptors are not only 
important for the gene transcriptions, the ligand free RARs are also necessary for the 
transcriptional repression for some biological process. Although the binary function model of 
RAR is widely found in in vitro studies, its role in in vivo was quite unclear. Using the Xenopus 
as a model organism for RAR repression function in development, Koide and colleagues (Koide 
et al., 2001) showed the active repression of RAR was required for normal head formation. In 
RARγ knockout mice, the  bone growth retardation is found together with dysmorphic 
epiphyseal plate (Williams et al., 2009). It is also showed the defective osteogenesis found in 
the RARγ knock out mice was due to loss of the transcriptional repressive activities of RARγ. 
Therefore, these recent findings have changed the traditional ways of RAR signalling during 
development.  
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Figure 1.5. Summary table of RARs expressions in different tissues and organs during 
development 
The table was adapted from (Dollé 2009) the permission to reuse this figure is obtained from 
the publisher. The data was essentially obtained from mouse embryo.  
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1.14. Using zebrafish as model of developmental biology 
In recent years, the teleost fish Danio rerio, commonly known as zebrafish has become 
a new model organism of developmental and genetics study. Zebrafish produces relatively large 
embryos and has the ability to breed all year round in the right temperature. Importantly, the 
eggs are fertilized externally which make it easy to adjust the time point of fertilization as well 
as observation of the developing embryo. Moreover, zebrafish embryo has rapid embryonic 
development. The fertilized embryo reaches the organogenesis stage within 24 hours. Because 
of its transparency, it is also easy to inject fluorescent dye to track the cells and to create 
transgenic lines for tissues of interest or genes.  
Zebrafish is also a model organism to create mutant lines. By treating the adult fish 
with mutagens, many mutant lines can be created by screening the embryos. Since the zebrafish 
genome has been sequenced, the interesting mutant lines can be further analysed to track down 
the gene responsible for the mutation. In the opposite way, the gene of interest can be knocked 
down by injection of morpholino antisense molecules and the embryonic phenotype can be 
analysed. However, morpholino efficiency reduces as the embryos grow further. Therefore, 
morpholino based gene knock down study is limited to early embryonic development. In very 
recent years, a method to selectively knock down targeted genes to create permanent mutant 
zebrafish line has been developed using zinc finger nuclease (ZFN), transcription activator like 
effector nuclease (TALEN) and cluster regularly interspaced short palindromic spaces 
(CRISPR) tools (Hisano et al., 2013; Barrangou et al., 2007; Hwang et al., 2013).  
Zebrafish has the similar mechanism of embryonic development to other vertebrates. 
Therefore, using the zebrafish mutant lines, many zebrafish disease models to human diseases 
have been identified. Zebrafish also plays an important model organism for drug screening. 
Drug screening and toxicity tests can be easily done by adding the drugs into the embryonic 
water and the developmental changes can be observed.  
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1.15. Zebrafish embryonic development summary  
The details of zebrafish embryonic development were described in (Kimmel et al., 
1995) as follow. All the observations regarding to the zebrafish embryonic development were 
documented at 28.5 degree Celsius. In general, the stages of zebrafish embryonic development were divided 
into zygote period, cleavage period, blastula period, gastrula period, segmentation period, pharyngula period, 
hatching period and early larval period.  
Zygote period (0-0.45hpf) - This period starts from the newly fertilization stage and ends in the cleavage stage. 
The period approximately lasts 40 minutes. 
Cleavage period (0.45hpf-2.15hpf) - During the cleavage stage, the meroblastic cell divisions start to occur at 
every 15 minutes. A meroblastic pattern is defined as incomplete divisions of cells at the certain side of the 
fertilized egg in which the cytoplasm of divided cells are still interconnected. The total of six cells cycles are 
formed during the cleavage period resulting in the 64 newly divided cells lasting approximately two hours. 
During the cleavage cell division, the size of the cells becomes smaller after each cycle. 
Blastula period (2.15hpf-5.15hpf) - After 64 cell division cycles in cleavage stage, the embryo enters into 
blastula period around 2hpf (hour post fertilization). The blastula period is characterized by three main changes 
which are mid blastula transition (MBT), the yolk syncytial layer (YSL) formation and epiboly formation. 
MBT is the transitional period in which the decline of maternal RNA level and rise in zygotic RNA level. 
During this transition, the rate of cell divisions becomes slower and the zygote transform into ball-shaped. A 
new layer of cells is also formed known as YSL. The cells at the animal pole become oblong and start to 
migrate to the vegetal pole.  
Gastrula period (5.15-10h) - In brief, the main characteristic of gastrula period is major cell movements. The 
cells from animal pole where most of the cytoplasm and nucleus are present migrate to the vegetal pole where 
the most of yolk is present. During this movement, the three germ layers are formed known as ectoderm, 
mesoderm and endoderm. The embryo gradually transforms from the dome stage to tail bud stage where two 
buds can be seen in both poles of.  
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Segmentation period (10-24hpf) - Both buds from the head and tail regions go through the massive 
morphological transformation during segmentation period. The size of both head and tail buds became larger 
and the first somite is formed in the trunk region around 10hpf followed by waves of somites come from the 
tail bud which is now also known as pre-somitic mesoderm. At the same time, the cells in the head bud start to 
transform into the optic capsules, forebrain and midbrain. Segmentation period is completed after 30 somites 
are formed in clock and wavefront patterns.  
Pharyngula period (24-48hpf) – During this period, the embryo goes through dramatic organogenesis. Eyes, 
heart, circulation, pectoral fin, pigments are formed during this period.  
Hatching period (48-72hpf) – As the name suggest, the embryo hatches from the chorion just after 48hpf. The 
other obvious changes are pharyngeal arches formation and mouth formation.  
Early larval period (after 3dpf) - Most of the morphogenesis are completed after 3dpf and the embryo starts to 
grow rapidly. The yolk sac is depleted after 5dpf and swimming bladder is formed. The larvae grow into 
sexually mature adult at 3 months old stage. 
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Figure 1.6.  The stages of zebrafish embryonic development.  
The picture was adapted from Kimmel et al 1995 with the copy right clearance from John 
Willey and sons publishers (License Number: 3620160782752) 
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1.16. RA signalling during zebrafish development 
                Like in other vertebrate embryos, RA plays an important role in zebrafish embryonic 
development and is involved in axis formation, somitogenesis and the formation of pharyngeal 
arches, hindbrain, pancreatic and pectoral fin. As RA is a morphogen (a molecule which is 
important for morphogenesis), the signalling needs to be tightly regulated. Therefore, as in the 
embryonic development of  other vertebrate, RA signalling in zebrafish embryonic development 
involves the source of vitamin A, the RA synthesizing enzyme, the RA degrading enzyme and 
the RA receptors.  
                 The source of vitamin A in zebafish embryo comes from yolk sac. The zebrafish 
oocyte derives from oogonial stem cell population and undergoes vitellogenesis during 
maturation. The oocyte starts to collect the yolk proteins including vitamin A which come from 
the blood stream of adult liver during meiotic prophase (Gilbert 2000). Although the transport 
route of retinol from the zebrafish yolk sac to the developing embryo has not been properly 
mapped, it can be predicted using the pattern of expressions of the proteins which carry and 
transport the retinol in the developing zebrafish. As in the mammalian system, the first protein 
of the transport chain is zebrafish RBP4 or rbp4 which collects the retinol from the yolk sac. 
There is no evidence of rbp4 expression in zebrafish until somitogenesis. At 12hpf (hours post 
fertilization), rbp4 expression is found in the yolk syncytial layer cells which lie between the 
yolk sac and the developing embryos (Li et al., 2007), suggesting rbp4 may be important for 
retinol transfer from the yolk to the developing embryo. Visualization of intrinsic RA in 
transgenic reporter zebrafish (Shimozono et al., 2013) also shows the intrinsic RA is seen in 3 
somite stage which is around 11-12hpf. The transmembrane protein, stra6, which import 
extracellular retinol into the cell cytoplasm, also expresses at 12hpf (Isken et al., 2008). 
Interestingly, rbp4 morpholino injected zebrafish embryos shows abnormal yolk sac retention.     
Like other organisms, zebrafish embryos express two orthologous alcohol 
dehydrogenases (adh). Adh proteins are the catalytic enzymes which are involved in the 
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transformation of retinol (vitamin A) to retinaldehyde. They are adh5 and adh8. Adh8 has two 
isoforms in zebrafish, adh8a and adh8b. adh5 expression starts ubiquitously at 50% epiboly 
stage (Thisse et al., 2004). Adh8b expression starts during somitogenesis stage and is limited to 
the yolk syncytial layer cells (Thisse et al., 2004). However, the adh8a expression patterns have 
not been reported.  
As mentioned above, retinaldehyde dehydrogenase (Raldh) is the key enzyme in RA 
synthesis. Although there are three raldhs,raldh2, raldh3 and raldh4, raldh2 is assumed to be 
the most important gene for RA synthesis because the patterns of raldh2 expression overlap 
with the patterns of RA reporter transgene expression (Perz-Edwards et al., 2001). Whole 
mount in situ hybridization for zebrafish raldh2 (Grandel et al., 2002) shows that the expression 
starts at 30% epiboly stage (Figure 1.7).  Strong expression is found during later epiboly stage. 
During somitogenesis stage, the expression is found in the developing somitic mesoderm rather 
than pre-somitic mesoderm (PSM) which is the stem cell zone. In 20 somite stage, the 
expression is found in pharyngeal arch primordium and the eyes. From 26hpf, the expression is 
also detected in the pectoral fin bud area but the expression disappears later on. From 36hpf, the 
expression is present in the brain although the expression in the other part of the embryo 
disappears.  
The other two zebrafish raldh family members, raldh3 and raldh4 expression patterns 
are also been analysed (Liang et al., 2008). These two genes express much later than the 
previous one. raldh3 expression starts from 10hpf in the eye primordium until 19hpf. From 
28hpf, the expression is limited to the ventral eye area and at 32hpf, the expression is also found 
in the otic vesicle. raldh4 expression starts from 2dpf and its expression pattern is limited to the 
liver and intestine. Interestingly, there is no raldh1 gene in zebafish which is orthologous to 
mammalian RALDH1 (Liang et al., 2008).  
  The synthesized RA functions through its nuclear receptors. There are three main 
retinoic acid receptors in mammals which are RARα, RARβ and RARγ. However, zebafish has 
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only two receptors, rar-alpha (rara) and rar-gamma (rarg). Being teleost (ray-finned fish 
species) and teleost genes are duplicated; both zebrafish receptors have two sub-types, which 
are raraa, rarab, rarga and rargb (Hale et al., 2006; Waxman and Yelon 2007).  
The tissues or cells which do not need RA signalling during development are prevented 
from the teratogenic effects of RA by synthesizing cyp26. There are three cyp26 genes in 
zebafish which are cyp26a1, cyp26b1 and cyp26c1. cyp26a1 expression starts from 50% to 75% 
epiboly during the gastrulation period (Dobbs-McAuliffe et al., 2004; Kudoh et al., 2002) 
(Figure 1.8). The other areas of cyp26a1 expression include the tail bud during somitogenesis 
stage, ventral part of somites, growing pectoral fin, notochord, eye and pharyngeal arches. 
Comparative analysis of double in situ hybridization of cyp26a1 and raldh2 shows non-
overlapping patterns of expression between the synthesizing and degrading enzymes (Dobbs-
McAuliffe et al., 2004). cyp26b1 expression is also very similar to cyp26a1 expression (Zhao et 
al., 2005). However, its expression in the tailbud during somitogenesis is transient and the 
expression in the pectoral fin is restricted to the growing edge. cyp26c1 expression is limited to 
the hindbrain during gastrulation period and found in the brain and the pectoral fin during the 
period of organogenesis (Gu et al., 2005).  
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Figure 1.7. raldh2 expression during zebrafish embryonic development.  
The picture was adapted from (Grandel et al., 2002) and the permission to reuse this figure is 
obtained from the publisher. Whole-mount in situ hybridisations showing raldh2 expression in 
the zebraﬁsh embryo and larva at (A) 30% epiboly, (B-E) gastrula, during (F-I) somitogenesis, 
and (J-R) larval stages. (A) Marginal view, animal pole is upwards. (B, D) Animal view, dorsal 
is upwards. (C,G) Dorsal view, animal/anterior is upwards. (E) Sagittal section along the animal 
vegetal axis. (F) Lateral view, anterior is upwards. (H) Cross section perpendicular to 
anteroposterior axis. (H inset) Dorsolateral view, anterior is to the left. (I,J,L,P) Lateral view, 
anterior is to the left. (K,M,O,Q,R) Dorsal view, anterior is to the left. (N) Ventral view, 
anterior is to the left. anterior left, dorsal top; (D,F,H,J,L,N) dorsal view, anterior left; arrow 
indicates the developing eye region or the ventral retina of eye and the arrow head does the otic 
vesicle. (B) 14 hpf; (C–D) 19 hpf; (E–F) 24 hpf; (G–H) 36 hpf; (I–J) 2 dpf; (K–L) 3 dpf; (M–N) 
5 dpf; (O) 7 dpf. 
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Figure 1.8. cyp26a1 expression during zebrafish embryonic development.  
The picture was adapted from (Dobbs-McAuliffe et al., 2004) according to the 
permission to reuse from the publisher (License Number-3636520286688). Analysis 
of cyp26a1 expression in zebrafish during the first 48hpf of development using in situ 
hybridization. (A,C) dorsal right, anterior top. (B,D,E) dorsal forward, anterior top 
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(F,G, I–L) dorsal top, anterior left. (H) dorsal forward, anterior left. Expression 
of cyp26a1 during epiboly (A,B) is found in the presumptive neural plate and around the 
blastoderm margin, but is excluded from the presumptive notochord region (B, black arrow). 
(C-E) cyp26a1 expression in the presumptive neural tube condenses, forming two bands of 
expression corresponding to the presumptive forebrain (fb) and midbrain (mb). At bud stage 
(C,D) we also see a band of expression in the middle portion of the embryo (black asterisk). 
(C,F,G,I) cyp26a1 is expressed in the tailbud throughout growth of the tail. By 24hpf 
(I) cyp26a1 is down regulated in the trunk and tail. During somitogenesis cyp26a1 is expressed 
in the ventral boundary of somites (G, white arrowheads), in the developing branchial arches 
(F,H,J, white arrow), and in the posterior notochord (I, black arrow). Post-somitogeneis 
expression of cyp26a1initiates in the neural retinal (K r, retina, l, lens), base of the pectoral fin 
(L, white asterisk), and cells in the hindbrain (L, black arrowhead). 
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1.17. Patterns comparison between RA synthesizing genes and RARs 
When the patterns of raldh2 expression and rar expressions in the developing zebrafish 
are compared, the results show that not all of the rar isoforms overlap with raldh2 expression 
(Grandel et al., 2002; Waxman and Yelon 2007). At 30 to 40% epiboly stage, the weak 
expression of raraa is localized in the dorsal area of animal pole (Figure 1.9) while the raldh2 
expression at the same time point is limited in the ventral side of blastula. Although many 
tissues of developing zebrafish embryo express raldh2 during early embryonic development, 
the question is whether this gene transcription expression is associated with protein translation 
and RA synthesis. Visualization of intrinsic RA shows (Shimozono et al., 2013) the first wave 
of synthesized RA starts to be seen at 75% epiboly stage although the transcripts of raldh2 are 
detected at 30% epiboly stage. Using the transgenic zebrafish which has the transgene of 
cyp26a1:eYFP (Li et al., 2012), RA signalling is visualized using cyp26a1 promoter which has 
a RARE sequence. This transgenic line also confirms the gene expression at 75% epiboly stage 
in the area of presumptive neural plate. Therefore, the regions of RA synthesis and RA 
signalling overlap at 75% epiboly stage. Interestingly,  only rarab is expressed in the same 
region at 75% epiboly stage (Waxman and Yelon 2007). In tailbud stage, raldh2 is express in 
the somites while rarga and rargb are strongly expressed in the pre-somitic mesoderm (PSM). 
During pectoral fin formation, no RA signalling or RA synthesis is reported in the growing 
pectoral fin. Non-overlapping patterns of expression are associated with rarg and raldh2 while 
rarg expression patterns overlap with cyp26a1 expression patterns in tailbud, pectoral fin and 
pharyngeal arches. Therefore, the differential expression patterns between rarg and raldh2 
suggest zebrafish rarg has little or no contact with RA.  
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Figure 1.9. rar expressions during zebrafish embryonic development.  
The picture was adapted from Waxman and Yelon 2006 with the permission to reuse from the 
publisher (License Number- 3636520796934 ). Comparison of zebrafish rar expression patterns 
from 40% epiboly through 24 hpf. ISH depicts expression patterns of raraa, rarab, rarga, and 
rargb. A–D: Lateral views of embryos at 40% epiboly, animal pole at the top, dorsal on the 
right. Arrow in A indicates dorsal expression. E–H: Lateral views at shield stage. I–L: Lateral 
views at 80% epiboly. Arrows in K indicate low expression around the margin. M–P: Lateral 
views at the tailbud stage, anterior at the top. Arrow in O indicates anterior mesendoderm 
expression. Arrowhead in P indicates higher anterior expression. Arrow in P indicates tailbud 
expression. Q–T: Lateral views at the 15-somite stage. U-X: Lateral views at 24 hpf. 
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1.18. Overlapping expressions patterns between zebrafish rarg and cyp26a1 
For many years, RAR functions have been studied in cell proliferation, differentiation, 
developmental biology and cancers assuming RARs as transcriptional activators. The functional 
studies were mainly done by studying the specific receptor knock-out phenotypes. For example, 
RARα knock-out mice were used to study the loss of function study for RARα gene and no 
observable phenotype was found (Li et al., 1993). RARβ knock-out mice had reduced weight 
and an ocular defect (Ghyselinck et al., 1997). Both RARγ subtypes knock-out in mice shows 
loss of growth, cartilage defect and vertebrate malformation (Subbarayan et al., 1997). 
Therefore, it was generally thought gene knock out studies were important to study RAR 
functions based on loss of RAR transcriptional activations. However, Williams and colleagues 
proposed an interesting function of RARγ as “ligand-less repressor function” based on their 
study in knock-out mice cartilage (Williams et al., 2009).  In their study, they found that the 
avascular zone of long bone cartilage has high level of RARγ expression and RARγ (-/-) mice 
show defective cartilage formation. They also suggested that avascular zone does not receive 
liver synthesized retinoid, suggesting that RARγ repressor roles are involved in normal bone 
growth. Therefore, this murine data suggests RARγ may have an important role in the absence 
of ligand. Koide and colleges also showed ligand free RAR transcriptional repression is 
required for the normal head formation in Xenopus (Koide et al., 2001). A very recent paper 
also mentions ligand free RARγ is required for the normal body axis extension and treatment 
with RARγ specific agonist caused the loss of body axis extension (Janesick et al., 2014). 
Therefore, co-expression patterns of rarg and cyp26a1 in PSM and pharyngeal arches of 
zebrafish embryonic development also suggests rarg may also have functions in the absence of 
ligands.  
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1.19. Hypothesis 
The main objective of the project is to reveal the importance of rarg during zebrafish 
embryonic development and tissue regeneration using a novel synthetic RARγ specific drugs 
that were previously developed for the treatment of the malignant conditions (Hughes et al., 
2006). Treating embryos with RARγ specific synthetic retinoids was performed to target the 
developmental expression of rarga and rargb in zebrafish. If zebrafish rarg plays an important 
role during its ligand-free state, then targeting the receptor with a specific ligand was expected 
to result in triggering transcriptional activation. Therefore, cells or tissues which need to have 
ligand-free rarg might be expected to have developmental changes as a result of receptor 
specific agonist treatment. In summary, the main tasks of the projects were: 
 To examine the dose-dependent effects of RARγ agonist treatment on zebrafish 
embryonic development. To analyse which tissues or cells were affected by RARγ 
agonist treatment in order to identify which cells and signalling pathways were 
involved 
 To examine which mechanisms underpinned this pathway 
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Chapter 2 
Materials and Methods 
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2.1. Zebrafish Husbandary  
Stocks of the wild-type AB strain of zebrafish were maintained in the fish unit of the 
Biomedical Research facility in Aston University according to UK Home Office guidelines. 
The unit had a 14/10 hours day/night cycle according to zebrafish husbandry guidelines 
(Kimmel et al., 1995). For breeding, the sexually mature male and female zebrafish were 
selected from the group and transferred to a breeding tank. The breeding tank consists of two 
compartments for each male and female zebrafish which were separated by a divider. Breeding 
preparation was done in the late evening to minimize the stress to the zebrafish. In the following 
morning, the divider was removed from the tank to make the physical contact between the male 
and the female zebrafish. The embryos were collected using a tea strainer and transferred into 
petri dishes (SLS, Hessle, UK) of Hank’s solution (Molekula, Dorset, UK) or E3 fish media 
(Wile et al., 2009). 
 
Full Strength Hank's Formula 
0.137 M NaCl  
5.4 mM KCl  
0.25 mM Na2H PO4  
0.44 mM KH2 PO4  
1.3 mM CaCl2  
1.0 mM Mg SO4  
4.2 mM NaH CO3 
 
E3 Buffer Formula 
5 mM NaCl 
0.17 mM KCl 
0.33 mM CaCl2 
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0.33 mM MgSO4 
 
Following breeding, zebrafish eggs were kept in an incubator at 28
o
C in petri dishes in 
a 4ml solution of Hank’s solution or E3 fish media. Experiments using transgenic reporter fish 
were performed at the National Institute of Genetics (NIG) in Mishima, Japan, with husbandry 
according to NIG Institutional guidelines (Westerfield, 2000).  Two transgenic fish lines, 
SAGFF155A, hspGFFDMC28B, and hspGFF55B were generated by the Gal4-UAS method 
(Asakawa et al., 2008).  In the SAGFF155A and hspGFFDMC28B zebrafish, the gene trap and 
enhancer trap constructs are integrated within the hoxc11a and hoxb13a genes, respectively. 
Therefore, Gal4FF expression is likely to recapitulate that of the endogenous genes (Asakawa et 
al. 2008). In hspGFF55B, Gal4FF is expressed in the somite and heart. The HGn39D line was 
used to visualise the lateral line (Pujol-Martí et al., 2012). The transgenic zebrafish reporter 
line, Tcf:mini-p line, was used to visualize canonical wnt signalling (Shimizu et al., 2012), 
which was kindly provided by Dr Ishitani (Kyushu University). For Gal4-UAS breeding, either 
male or female adult zebrafish of the Gal4 line was crossed with UAS-GFP reporter zebrafish 
as pair-wise crossings in breeding tanks. The male and female zebrafish were separated using a 
barrier the evening before the actual day of breeding. The barrier was removed on the following 
morning to allow male and female mating and fertilised eggs were collected within 30-60 
minutes of this using a strainer.  
Neuronal specific HuC:rfp transgenic line, apc (adenomatous polyposis coli) mutant 
line and krt4p (keratin)-gal4:uas-dkk2 (dickov)-rfp transgenic zebrafish lines were kindly 
provided by Dr Hirinori Wada.  
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2.2. RARγ reagents: preparation and treatment protocols  
The RARγ specific agonist and antagonist (Hughes et al., 2006) were kept as 10mM 
stock solutions dissolved in 50% DMSO and 50% methanol. These stocks were diluted with 
100% DMSO to give a working stock solution at 100μM according to previously published 
studies (Li et al., 2010). These working stocks were then further diluted with Hank’s solution or 
E3 media to the final concentrations used for the treatments of zebrafish embryos as given in 
Results. A control solution of a 50%:50% DMSO:methanol carrier alone stock further diluted 
into 100% DMSO and then into Hank’s or embryo media was prepared using the exact dilutions 
that were used for the RARγ reagents. Following treatment of zebrafish embryos by immersion 
in E3 media supplemented with the RARγ reagents or carrier alone at 4 hours post fertilisation 
(hpf) (or at other times as indicated in Results), the treated and control embryos were incubated 
at 28
o
C (Kimmel et al., 1995). Zebrafish embryos were treated with the RARγ agonist at 4hpf 
because the agonist is not subject to degradation and RARγ expression is detected at the 40% 
epiboly stage, which is around 5hpf (Waxman and Yelon 2007). 
atRA (all trans retinoic acid)(Sigma, St. Louis, USA) was also prepared in the same 
way to RARγ-specific agonist preparation. However, the 10mM atRA stocks were freshly 
prepared and not kept for more than two week because of its photosensitivity and degradation.  
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2.3. In situ hybridisation and immunolocalisation protocols 
In situ hybridisation for myoD expression was performed according to previously 
published methods (Thisse and Thisse 2008). In details, zebrafish embryos treated with the 
RARγ agonist (at 4hpf) and control embryos were harvested at 22hpf. Chorions were removed 
either  by pronase enzymatic digestion. 1% pronase (Sigma) solution was prepared in E3 media 
and warmed up to 28.5
o
C. The embryos were placed in 100ml beaker and covered with minimal 
amount of solution. The warm pronase solution was added to the beaker and the digestion was 
monitored until the chorions were torn. The pronase solution was rapidly removed and replaced 
with fresh embryo media up to 100ml. When the embryos were settled at the bottom of the 
beaker, the embryo media was poured away without disturbing the embryos at the bottom. The 
washing steps were repeated three times. The embryos were then anaesthetized with 0.4% 
tricaine (Sigma) and fixed in 4% paraformaldehyde (PFA) (Sigma) at 4
o
C overnight, before 
dehydrating in 100% methanol, also at 4
o
C overnight. The embryos were then serially 
rehydrated through decreasing alcohols (100%, 70%, 50%, 25% methanol in phosphate buffer 
saline (PBS)) for five minutes each and finally to phosphate buffered saline (PBS) alone for 5 
minutes four times. The rehydrated embryos were permeablelized with proteinase K (10μg/ml, 
Sigma) for 10 minutes. The digestion reaction was stopped by adding 4%PFA (Sigma) for 20 
minutes. The samples were then washed with PBS four times.  
In situ hybridisation was performed by incubating the embryos in hybridisation mix 
solution at 70
o
C for 5 hours, prior to a further overnight incubation at 70
o
C with the myoD 
probe (ZFIN:ZDB-GENE-980526-561). 
Hybridization mix (HM) formula 
-50% deionized formamide (Sigma) 
-5xSSC (Sigma) 
-0.1% Tween 20 (Sigma) 
-50μg ml/1 of heparin (Sigma) 
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-500μg ml/1 of RNase-free tRNA (Sigma) adjusted to pH 6.0 by adding citric acid (460 ml of 
1M citric acid solution for 50 ml of HM). 
 Following a series of washes in sodium citrate pre-warmed solutions (HM mix alone, 
75%HM mix + 25% 2xSSC, 50%HM mix + 50% 2xSSC, 25%HM mix +75% 2xSSC, 100% 
2xSSC for 10 minutes each and 0.2xSSC for 30 minutes each at 70
o
C)and then PBS and 
0.2xSSC serially diluted solutions (75% 0.2xSSC+25%PBS, 50% 0.2xSSC+50%PBS, 25% 
0.2xSSC+75%PBS and 100%PBS at room temperature for 10 minutes each) , the embryos were 
blocked with blocking buffer (1x PBT, 2% (vol/vol) sheep serum, 2 mg/ml of bovine serum 
albumin) for 3-4 hours at room temperature. Finally, the embryos were incubated overnight at 
4
o
C with anti-DIG-alkaline phosphatase antibody specific for the myoD probe (Invitrogen), 
Anti-DIG-alkaline phosphatase was replaced and the embryos were washed with PBS 
for 15 minutes each at room temperature six times. The embryos were then washed with 
alkaline Tris buffer for 5 minutes each three times. Immunopositivity was revealed using a 
staining solution of Nitro Blue Tetrazolium (NBT, Sigma) and  5-Bromo 4-Chloro 3-Indolyl 
Phosphate (BCIP, Sigma). The stained embryos were then transferred to glycerol (Molekula) 
for microscopy and imaging. 
Immunolocalisation was performed for the muscle marker, α-actinin, the neural crest 
marker, sox9, and the lateral plate mesoderm marker, tbx5, by adapting previously published 
methods (Codina et al., 2010). In brief,  RARγ agonist treated and control embryos were fixed 
in 4% PFA at 4
o
C overnight at the time points indicated in Results, then washed repeatedly in 
PBS-Tween (PBS-T: 90%:10%) before an enzymatic digestion with collagenase (1mg/ml, 
Sigma) for 75 minutes at 37
oC. The embryos were then incubated with antibodies specific for α-
actinin (1/100 dilution in PBS-T; Sigma) or sox9 (1/100 dilution in PBS-T, Clone ab76997, 
Abcam Ltd., Cambridge, UK) or tbx5 (Genetix, Irvene, USA) at 4
 o 
C overnight.  Embryos were 
then washed repeatedly in PBS-T prior to incubation with Alexa 594-conjugated anti-mouse 
antibodies for α-actinin or sox9 (1/250 dilution in PBS-T, Invitrogen Ltd, Carlsbad, USA) at 
4
o
C overnight, washing again in PBS-T, and then mounted in glycerol for microscopy and 
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image capture. For tbx5 immunolocalisation, embryos were similarly washed repeatedly in 
PBS-T after incubation with the primary antibodies, after which immunopositivity was revealed 
using biotin-anti rabbit secondary antibodies (1/400 in PBS-T; Vector Labs, Peterborough, UK) 
followed by further washes and incubation with streptavidin-linked FITC (1/50 in PBS-T; 
Vector Labs), adapting methods previously described (Johnson et al., 2001). 
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2.4. Alizarin red staining for bone, Oil Red O staining for lipid particles and acridine orange 
staining for apoptosis  
Alizarin red staining was performed to examine the presence of bone by adapting 
previously published methods (Li et al. 2010). In brief, RARγ agonist treated and control 
embryos were euthanized at 5 days post fertilisation (dpf) and fixed in 4% PFA at 4
o
C 
overnight, then washed in PBS-T prior to staining in a solution of alizarin red (96% of 0.5% 
KOH:4% of 0.1% Alizarin Red S;  Molekula) for 3  hours at room temperature. After staining, 
the embryos were washed and mounted in glycerol prior to microscopy and image capture.  
Oil red o staining was also adapted from (Li et al., 2010). The RARγ agonist treated 
and control embryos were euthanized at 5dpf and fixed in 4%PFA at overnight, then washed in 
PBS-T for 5 minutes. Then, the samples were stained with filtered 0.3% oil red o in 60% 
propan-2-ol in 2 hours. Thereafter, the samples were rinsed in PBST and mounted in glycerol 
for imaging.   
Acridine orange staining protocol was adapted from zfin.org. The alive RARγ agonist 
treated and control embryos were incubated in 0.05% acridine orange solution for 30 minutes at 
4
o
C. The embryos were then washed with fresh embryo media for three times before mounting 
in 3% methyl cellulose and imaging under fluorescent microscope.  
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2.5. Image capture and analysis            
Phase contrast or bright field digitised images were captured using either a Nikon 
DXM1200 camera attached to a Nikon SMZ745T stereomicroscope or a Leica DFX 300FX 
camera attached to a Leica MZ 16FA stereomicroscope or Jenoptik camera attached to Ceti 
inverted microscope. A Leica DFX 300FX camera, attached to a Leica MZ 16FA 
stereomicroscope, was also used to capture fluorescence images of the transgenic zebrafish 
embryos and of α actinin-immunostained embryos. Laser scanning confocal microscopy was 
performed with the Leica Microsystems DM6000B-SP57CS confocal system to generate z 
stacks of sox 9-and tbx5-immunostained zebrafish embryos. These were then converted into 3D 
projected images of the entire ventral-dorsal or lateral aspects. The projected images of sox9 
immunostained zebrafish embryos were used to quantify the number of sox9 immunopositive 
cells present in the total head region that was anterior from the anterior aspect of the otic 
vesicle. Phase contrast digitised images were captured at low magnification (x 4 lens) and these 
images were analysed to determine the embryo length along the antero-posterior axis using 
Image J software. 
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2.6. Caudal Fin Transection 
The AB strain or Tcf:mini-p transgenic zebrafish embryos at 2dpf or 3dpf, respectively, 
were anaesthetized with 0.4% Tricaine (Sigma) then placed on a glass slide and the caudal fin 
transected using a thin scalpel blade (SLS). The embryos were then transferred to fresh Hank’s 
saline or E3 media in an incubator at 28.5
o
C for those periods of fin re-growth indicated in 
results. The embryos were treated with the RARγ agonist (10nM) or carrier alone immediately 
following caudal fin transection. In some experiments, the AB strain embryos were treated with 
a RARγ specific antagonist at 3dpf (following RARγ agonist treatment at 2dpf) or subject to 
wash out of the RARγ agonist at 3dpf.   
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2.7. Statistical analysis 
Data was evaluated for normal distribution using the D’Agostino and Pearson omnibus 
normality test. One way or two way ANOVAs were used to assess the relationships between 
treatment of zebrafish embryos with different concentrations of the RARγ agonist and fish 
length or the growth of treated versus control embryos over time, with post hoc analysis. 
Student paired t-tests or Mann Whitney U tests were used to examine differences between 
treatment versus control groups for hox gene expression or the prevalence of Sox9 
immunopositive cells, according to whether the data was normally or not normally distributed, 
respectively. All statistical analysis was performed using GraphPad Prism software. Values 
were considered statistically significant, as indicated in Results, at P≤0.05 (*). Unless otherwise 
indicated all data have been presented as means ± standard deviations (SD) where a minimum 
of n=3 procedures were performed for all experiments. 
 
 
 
 
 
 
 
 
 
 
 
60 
 
Chapter 3 
Phenotypic characterization of RARγ agonist treated zebrafish embryos 
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3.1. Introduction 
The main question of this project is to investigate the importance of RARγ (zebrafish 
rarga and rargb) during zebrafish embryonic development. The gene expression patterns of 
zebrafish raldh2 which is responsible for RA synthesis and  zebrafish rarg expression patterns 
do not overlap during early zebrafish embryonic development (Grandel et al., 2002; Waxman 
and Yelon 2007). The patterns of  intrinsic RA synthesis using RA responsive reporter zebrafish 
line (Shimozono et al., 2013) overlaps with the expression patterns of cyp26a1:eYFP transgenic 
reporter zebrafish line (Li et al., 2012) in which RA signalling is visualized using cyp26a1 
promoter which has RARE sequence at 75% epiboly stage. Interestingly, the only rarab is 
expressed in the same region where RA is present at 75% epiboly stage (Waxman and Yelon 
2007) and the chromatin immunoprecipitation results show zebrafish RARα binds to RARE (Li 
et al., 2012). In tailbud stage, raldh2 is expressed in the somites (Dobbs-McAuliffe et al., 2004) 
while rarga and rargb are strongly expressed in the pre-somitic mesoderm (PSM) (Hale et al., 
2006; Waxman and Yelon 2007). During pectoral fin formation, both RA signalling and RA 
synthesis are reported to be present in the pectoral fin progenitor cells area of RA responsive 
reporter zebrafish line (Shimozono et al., 2013) or cyp26a1:eYFP transgenic reporter zebrafish 
line (Li et al., 2012). Therefore, non-overlapping patterns are found between rarg expression 
and raldh2 expression while rarg expression patterns overlap with cyp26a1 expression patterns 
in tailbud, distal edge of pectoral fin and pharyngeal arches. These non-overlapping expression 
patterns of rarg and raldh2 suggest that rarg does not function during development to activate 
RA responsive genes. Instead, a lack of rarg dependent transcriptional activity may be 
important and rarg may play a key role in repressing gene expression in its non-ligated state.  
The main objective of the project is to justify the importance of rarg during zebrafish 
embryonic development using a novel synthetic RARγ specific compound (Hughes et al., 
2006). Treating the zebrafish embryos with the RARγ agonist is expected to target the rarga 
and rargb in the developing zebrafish. If zebrafish rarg has the important role as ligand free 
receptor, targeting the receptor with specific ligand is expected to change the receptor 
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conformation resulting in triggering the transcriptional activation. Therefore, the tissues or cells 
which are needed to have the ligand free rarg for the transcriptional repression might have the 
changes as the result of receptor specific agonist treatment. The zebrafish embryos were 
initially treated with RARγ agonist at the dome stage, which is at 4hpf prior to the first 
expression of rarg in the epiblast at around 5.5hpf (Hale et al., 2006; Waxman and Yelon 
2007). 
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3.2. Treatment of zebrafish embryos with a RARγ agonist inhibited anterior-posterior growth.  
Like RA treatment, the RARγ agonist treatment to the zebrafish embryos caused the 
embryonic truncation. Treatment of zebrafish embryos at 4 hpf with the RARγ agonist was 
associated with clear morphological differences during development, with the main difference 
being a reduced anterior-posterior axis length at 3dpf (Figure 3.1). The cardiac oedema was also 
present. The effect on reduced anterior-posterior axis formation in RARγ agonist treated 
zebrafish embryos was dose-dependent (Figure 3.2). The concentration ranged from sub-nano 
molar level (0.625nM) up to 5nM RARγ agonist treatment on zebrafish embryos had no 
obvious effects on anterior-posterior axis growth but the dramatically reduced anterior-posterior 
axis length was observed from 10nM according to the increasing concentration (Figure 3.2). 
However, the effects of RARγ agonist on zebrafish anterioranterior-posterior axis length 
reached the highest level when the concentration was more than 80nM. The zebrafish embryos 
treated with the RARγ  agonist concentration more than 80nM also showed lack of hatching at 
3dpf which physiologically happens between 48hpf to 72hpf (Kimmel et al., 1995).  The data 
analysis showed the half inhibitory concentration was 14.59nM (Figure 3.2). Therefore, 10nM 
concentration was chosen to use the agonist effect on embryonic development compared to 
1nM or 100nM since the concentrations around 1nM produced the normal embryonic 
development and the concentrations around 100nM result in severe truncation and low survival 
rate. 
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Figure 3.1. Treatment of embryonic zebrafish with a RARγ agonist (10nM) at 4hpf was 
associated with a reduced anterior-posterior length at 3dpf.  
A representative phase contrast microscopy picture showing the left lateral view of RARγ 
agonist (10nM) treated and control AB strain zebrafish embryos at 3 days post fertilisation 
(dpf). The RARγ agonist (10nM) treated embryo length was markedly shorter than the control. 
Cardiac oedema was also evident (arrowed). Scale bars = 250μm. (n=3 independent 
experiments) 
 
RARγ agonist 
Control 3dpf 
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 Figure 3.2. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with a dose-dependent decreased in anterior-posterior length at 3dpf.  
Representative pictures are shown of the zebrafish embryos in the wells which were treated 
with different concentration of RARγ agonist (10nM) ranged from 0.625nM to 640nM.The 
sigmoid curve below shows the dose-response curve of the different concentration of RARγ 
agonist (10nM) plotted against the anterior-posterior axis length. The half inhibitory 
concentration, IC50 was 14.59nM. Treatment with of RARγ agonist (10nM) from sub-
nanomolar (0.625nM) to 5nM concentrations to the zebrafish embryos at 4dpf did not cause the 
obvious changes to the anterior-posterior axis formation in embryonic zebrafish development at 
3dpf. However, the dramatic changes in the RARγ agonist (10nM) treated zebrafish embryos at 
3dpf was observed when the RARγ agonist (10nM) concentration ranged from 10nM and the 
shorter anterior-posterior length was reversely proportionate to the RARγ agonist (10nM) 
concentration up to 100nM,i.e, the higher the concentration of RARγ agonist, the shorter the 
anterior-posterior axis was. However, the effects were not different in the zebrafish embryos 
which were treated with RARγ agonist (10nM) at the concentration over 100nM. Scale bar = 
5mm. (n=3 independent experiments) 
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3.3. Treatment of zebrafish embryos with the RARγ agonist might have affected 
somitogenesis. 
 Previous results show the effects of RARγ agonist treatment to the zebrafish embryos at 
4hpf caused reduced anterior-posterior axis formation in the 3dpf embryos. Somites are the 
main building blocks of body axis formation and somitogenesis in zebrafish embryos completes 
at 24hpf (Stickney et al., 2000). Therefore, there are two possibilities which caused the reduced 
anterior-posterior axis formation in RARγ agonist treated zebrafish embryos. The first 
possibility is RARγ agonist affected the somitogenesis, causing the reduced number of somites 
and reduced anterior-posterior axis. The second possibility is RARγ agonist did not affect the 
somitogenesis but inhibited further growth. To clarify the possible cause, the RARγ agonist 
treated embryos at different concentration were analysed at 1dpf, the time point in which 
zebrafish somitogenesis is completed (Stickney et al., 2000)  
 The results (Figure 3.3) show there was no significant difference in anterior-posterior 
length between control embryos and 5nM RARγ agonist treated embryos at 1dpf. However, the 
anterior-posterior length between the control embryos and the rest of RARγ agonist treated 
embryos (10nM, 20nM, 40nM and 80nM) were significantly different. Therefore, these 
evidences suggest RARγ agonist treatments affected the zebrafish somitogenesis. Moreover, 
two other changes were abnormal yolk sac formation and loss of anterior structures including 
eye formation in RARγ agonist treated zebrafish embryos (20nM, 40nM and 80nM) at 1dpf. 
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Figure 3.3. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with a reduced anterior-posterior axis length at 1dpf.  
Representative pictures are shown of the left lateral views of the zebrafish embryos treated with 
the different concentration ranged from 5nM to 80nM at 1dpf. The zebrafish embryos which 
were treated with RARγ agonist (10nM) at the concentration of more than 10nM had defective 
eye structures as well as abnormal yolk sac extension (arrowed). The graph showed the 
anterior-posterior lengths between 5nM and control embryo were not significant although the 
rest of different concentration are significantly different to the control. The data are normal and 
unpaired t-test was used for significance test. Scale bars = 0.5mm. The data was evaluated for 
normal distribution using the D’Agostino and Pearson omnibus normality test. P value ≤ 0.001 
(n=3 independent experiments) 
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3.4. The efficiency of RARγ agonist was lower than that of RA treatment to zebrafish 
embryonic development. 
Since RARγ agonist is a synthetic retinoid for RARγ (Hughes et al., 2006), the 
similarities between RARγ agonist and RA were also examined at different concentrations. 
Interestingly, RA treated zebrafish embryos had severe phenotypes such as shorter anterior-
posterir axis length than that of RARγ agonist treated zebrafish embryo at the same 
concentration as well as loss of anterior head structures including eyes (Figure 3.4.). Moreover, 
RA treated embryos had bigger yolk sac than RARγ agonist treated zebrafish embryos at the 
same concentration. However, these phenotypes found in RA treated zebrafish embryos were 
also present in the RARγ agonist treated embryos only when the concentrations were higher 
than 10nM. Therefore, these findings suggest RA had higher efficiency than RARγ agonist and 
treatment with 10nM RARγ agonist may have activated the selective receptors. 
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Figure 3.4. The efficiency of RARγ agonist (10nM) treatment was different from that of RA 
treatment to zebrafish embryonic development at 1dpf.  
Representative pictures are shown of the left lateral views of the embryos treated with the 
concentration ranged from 5nM to 80nM of RARγ agonist (10nM) and RA. At the same 
concentration, the severities of RARγ agonist (10nM) and RA on the zebrafish embryos were 
not the same. RA treated embryos had severely truncated body as well as malformed anterior 
head including eye formation even at 5nM. However, the malformed anterior structures in 
RARγ agonist (10nM) treated embryos were only found when the concentration was higher 
than 10nM. Scale bar=0.5mm (n=3 independent experiments) 
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3.5. The zebrafish chorion permeability did not interfere with the RARγ agonist efficiency.   
Zebrafish chorion is a natural protective barrier for certain-sized molecules (Hagedorn 
1998). Moreover, it has been reported that the interaction and permeability of chorion to the 
toxic chemicals (Henn and Braunbeck 2011). Thus, the natural properties of zebrafish egg 
chorion may provide the false interpretation of the experimental results in RARγ agonist treated 
zebrafish embryos. Therefore, the control experiments were done to investigate the difference in 
the RARγ agonist drug efficiency by removing the zebrafish chorion with pronase. 
The zebrafish embryos were treated with the RARγ agonist (10nM) at 4hpf with or 
without chorion after treatment with pronase. The results showed there was no significant 
difference in anterior-posterior axis length at 3dpf between RARγ agonist treated chorion intact 
and chorion-removed embryos (Figure 3.5). Therefore, this result suggests there were no 
interference of zebrafish chorionic membrane on the interaction and permeability of RARγ 
agonist.  
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Figure 3.5. Zebrafish chorion permeability did not interfere with the RARγ agonist (10nM) 
efficiency. 
The bar graph shows the comparison of the anterior-posterior axis length between RARγ 
agonist (10nM) treatment to the embryos in which chorions were removed by pronase treatment 
and to those which had intact chorion at 3dpf prior to the RARγ agonist (10nM) treatment. The 
results show there was no significant difference between chorion removed RARγ agonist 
(10nM) embryos and chorion intact RARγ agonist (10nM) treated embryos. The length of 23 
chorion removed embryos and 33 chorion intact embryos were measured for this experiment.  
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3.6. Treatment of zebrafish embryos with the RARγ agonist caused the slow growth rate after 
2dpf. 
Treatment with RARγ agonist to the zebrafish embryos at 4hpf caused shorter anterior-
posterior axis length at 1dpf compared to that of control embryos, suggesting the somitogenesis 
might have been affected by RARγ agonist in the treated embryos. However, it is still not clear 
whether the RARγ can inhibit the further growth of the treated zebrafish embryos. Therefore, 
the changes in the anterior-posterior length in RARγ agonist treated and control embryos were 
analysed from 1dpf to 5hpf.  
The results showed there was a marked difference in the growth patterns between 
RARγ agonist treated and control embryos from 1dpf to 5dpf (Figure 3.6). From 1dpf to 2dpf, 
RARγ agonist treated and control embryos had a significant growth. However from 2dpf to 
5dpf, the control embryos had the increased in the anterior-posterior axis length although the 
RARγ agonist treated embryos did not have significant increase in their anterior-posterior axis 
length. Therefore, this result suggests RARγ-agonist treatment caused the growth retardation.  
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Figure 3.6. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with reduced growth rate. 
A representative line graph id shown the changes in the anterior-posterior axis length of RARγ 
agonist (10nM) treated (10nM) and control embryos from 1dfp to 5dpf. The length of RARγ 
agonist (10nM) treated and control embryos show the gradual increase pattern from 1dpf to 
2dpf. However, from 2dpf to 5dpf, the anterior-posterior axis length of RARγ agonist (10nM) 
treated embryos did not increase compared to the control embryos’ growth. (n=3 independent 
experiments) 
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3.7. Treatment of zebrafish embryos with the RARγ agonist caused the progressive cardiac 
oedema.  
 RARγ agonist treated embryos were associated with visible cardiac oedema at 3dpf 
(Figure 3.1). Therefore, the cardiac oedema development in RARγ agonist treated embryos was 
further analysed. The beating heart in normal wild type embryos which are grown at optimal 
temperature is present at 42-48hpf (Kimmel et al., 1995). Therefore, the progress of cardiac 
oedema in RARγ agonist treated embryos was analysed from 1dpf.  
Since the heart formation in the developing zebrafish embryos is not complete until 42-
48hpf (Kimmel et al., 1995), both RARγ agonist treated and control embryos had no visible 
heart at 1dpf (Figure 3.7). However, RARγ agonist embryos had a small cardiac oedema at 2dpf 
while the control embryos had a visible normal heart at the same age. At 3dpf, the cardiac 
oedema was strictly localised to the heart area in the RARγ treated embryo at 3dpf. However, 
the oedema was spread posteriorly along ventral side of the body. The changes in the circulation 
were also found in RARγ treated embryos at 4dpf (Figure 3.8). The changes found in the RARγ 
agonist treated embryos at 4dpf were slower circulation, dilated and congested the common 
cardinal vein and the accumulated blood cells. The heart of RARγ agonist zebrafish embryos 
may not have fully functional stroke because the fluid retention in the cardiac oedema may have 
the pressure against the cardiac chamber probably resulting in cardiac induced hypoxic state. If 
the heart did not pump out the required amount of blood, the blood in the vein may have 
congested. Therefore, this circulation changes may be the evidences of the cardiac oedema 
progression.  
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Figure 3.7. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with progressive cardiac oedema throughout the development from 2dpf to 4dpf and bigger 
yolk sac.  
The representative pictures show the progressive cardiac oedema in the RARγ agonist (10nM) 
treated embryos from 1dpf to 4dpf. Heart formation is not completed until 42hpf to 48hpf. 
Therefore, there was no obvious difference in the heart formation between RARγ agonist 
(10nM) treated embryos and control embryos at 1dpf. However, there was slight difference in 
the heart appearance between RARγ agonist (10nM) treated and control embryos, which is 
visible at 2dpf. However at 3dpf, a swelling is found in the heart area of RARγ agonist (10nM) 
treated embryos but not in control embryos. Moreover, the cardiac oedema was localized at the 
heart area at 3dpf but the oedema spread posteriorly to the yolk sac area at 4dpf in the RARγ 
agonist (10nM) treated embryos.  Moreover, the yolk sac size of RARγ agonist (10nM) treated 
embryos was bigger than those of control embryos. Scale bar=250µm (n=3 independent 
experiments) 
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Figure 3.8. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with slow circulation in the common cardinal vein.  
The representative pictures show the left lateral views of the tails in RARγ agonist (10nM) 
treated and control zebrafish embryos showed the evidences of slow circulation and 
accumulation of blood cells in the common cardinal vein of RARγ agonist (10nM) treated 
embryos at 4dpf. Therefore, the common cardinal vein in RARγ agonist (10nM) treated 
embryos was congested and dilated with the blood cells at 4dpf. Scale bar=250µm (n=3 
independent experiments) 
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3.8. Treatment of zebrafish embryos with the RARγ agonist caused the loss of lipid molecules 
in the inter-somitic vessels.  
The RARγ treated embryos showed the slow growth, congested yolk sac and the bigger 
yolk sac. The yolk sac is the source of nutrients for the zebrafish embryonic development until 
independent feeding at 5dpf (Kimmel et al., 1995) and consists of lipid molecules and vitamin 
A. Therefore, the cardiac oedema, slow circulation and the bigger yolk sac in the RARγ treated 
embryos suggests RARγ treatment might have affected the lipid distribution in the RARγ 
treated embryos. Hence, the lipid distribution in RARγ agonist treated embryos were examined 
using oil red o staining which is a dye for neural lipids, triglyceride and some lipoproteins.  
The oil red o staining results showed red coloured particles were present in the inter-
somitic vessels in the trunk region of the control embryos at 5dpf while these particles were 
absent in the same area of  RARγ agonist treated embryos at the same time point. Therefore, 
this evidence suggests treatment with RARγ agonist was associated with the lack of fat particles 
in the inter-somitic vessels (Figure 3.9). Lack of fat particles might be the secondary effects of 
cardiac oedema which failed to distribute the fat particles from the yolk sac to the inter-somitic 
vessels. Moreover, fat particle distribution failure might also be the reason to the bigger yolk 
sac in the RARγ agonist treated embryos as well as the slower embryonic growth.   
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Figure 3.9. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with the loss of fat particles within the inter-somitic vessels.  
The representative pictures show the left lateral views of the trunks in RARγ agonist (10nM) 
treated and control embryos at 5dpf. The lipid particles were stained with oil red o and 
visualized in the red colour. The representative results showed RARγ agonist (10nM) treated 
embryos had lack of red coloured lipid particles in the inter-somitic vessels while these red 
particles were present in the control embryos at 5dpf. . Scale bars = 250µm. (n=3 independent 
experiments) 
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3.9. Treatment of zebrafish embryos with the RARγ agonist caused the loss of caudal fin 
formation.  
 Another phenotype found in RARγ agonist (10nM) treated embryos was loss of caudal 
fin formation. Normal caudal fin formation in zebrafish embryos is found from 2dpf (Kimmel et 
al., 1995). Therefore, there was no obvious changes in the caudal fins of RARγ agonist treated 
embryos at 3dpf. However, the caudal fin was clear visible in the control embryos at 3dpf while 
RARγ agonist treated embryos had loss of caudal fin (Figure 3.10). Normal fin mesenchyme 
can be found in the control embryos but this structure was not well developed in RARγ agonist 
treated embryos.  
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Figure 3.10. Treating embryonic zebrafish with RARγ agonist (10nM) was associated with 
the loss of caudal fin formation.  
The representative pictures show left lateral view caudal fin of RARγ agonist (10nM) treated 
and control embryos at 3dpf. Wide and broad caudal fin mesenchyme was present in the control 
embryos while this mesenchyme was missing in RARγ agonist treated embryos. Arrow 
indicates the reduced and slightly kinked caudal fins that were observed in the RARγ agonist 
treated embryos. Scale bars = 250µm. (n=3 independent experiments) 
 
 
  
Control RARγ agonist  
3dpf 3dpf 
85 
 
3.10. Treatment of zebrafish embryos with the RARγ agonist caused the loss of pectoral fin 
formation.  
Previous studies have reported that RA signalling is crucial for pectoral fin induction 
via tbx5 gene expression which is the transcription factor (Begemann et al., 2001; Grandel et 
al., 2002). Pectoral fin outgrowth from the fin bud can be seen from 30hpf in normal zebrafish 
development (Kimmel et al., 1995) and the full developed pectoral fin can be clearly seen at 
3dpf.  
The pectoral fin was absent in the RARγ agonist (10nM) treated embryos at 3dpf while 
the control embryo had a grown pectoral fin at the same stage (Figure 3.11). Although the 
pectoral fin was absent in the RARγ agonist treated embryos, there was a visible pectoral fin 
bud present in the RARγ agonist treated embryo. Therefore, the pectoral fin formation was lost 
in RARγ agonist treated embryos.  
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Figure 3.11. Treatment of embryonic zebrafish with the RARγ agonist (10nM) was associated 
with the loss of pectoral fin formation at 3dpf.  
The representative pictures show the dorsal views of RARγ agonist(10nM) treated and control 
embryos at 3dpf in the pectoral fin area. The control embryo had well grown pectoral fin at 3dpf 
while the pectoral fin formation was absent in RARγ agonist (10nM) treated embryos at the 
same stage. However, the pectoral fin bud was present in RARγ agonist (10nM) treated 
embryos (arrowed). Scale bars = 250µm. (n=3 independent experiments) 
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3.11. Treatment of zebrafish embryos with the RARγ agonist caused the loss of pharyngeal 
arches.  
 RARγ agonist treated embryos were associated with changes in the head morphology 
including smaller eyes (Figure 3.12). In details, the head of RARγ agonist zebrafish embryos 
was smaller than that of the control embryo at 3dpf. Moreover, the shape of RARγ agonist 
treated embryos was round while that of the control embryos was rectangular in shape. RARγ 
agonist treated embryos also showed lack of pharyngeal arches inside the head whilst these 
structures were present in the control embryos at 3dpf. Pharyngeal arches are the supportive 
structures of the head. They are originated from the cranial neural crest and differentiate into the 
cranial cartilage and bone at later time point which is 5dpf. Therefore, this finding suggests 
RARγ agonist might have affected the cranial neural crest in RARγ agonist treated embryos.  
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Figure 3.12. Treatment of embryonic zebrafish with RARγ was associated with the loss of 
pharyngeal arches at 3dpf and loss of cranial bones at 5dpf.  
The representative pictures show the head dorsal views of RARγ agonist (10nM) treated and 
control embryos at 3dpf. The control embryos head was bigger than that of RARγ agonist 
embryo and rectangular in shape while the RARγ agonist treated head was round in shape. 
Moreover, RARγ agonist treated embryos had loss of pharyngeal arches (arrowed) while these 
arches were present in the control embryos at 3dpf (arrowed). Scale bars = 250µm. (n=3 
independent experiments) 
RARγ agonist  
Control 
3dpf 
3dpf 
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3.12. Discussion 
 The results show RARγ agonist treatment caused the pleiotropic effects on the zebrafish 
embryonic development when the embryos were treated with RARγ agonist at 4hpf. These 
effects included shorter anterior-posterior axis, slower growth rate, bigger yolk sac, cardiac 
oedema, venous dilation, lipid particle loss in the inter-somitic vessel, lack of caudal fin, 
pectoral fin and pharyngeal arches. Among them, shorter anterior-posterior axis in RARγ 
agonist treated embryos may be related to the cardiac oedema, bigger yolk sac, venous dilation 
and lipid particle loss in addition to the loss of somites. RARγ agonist treated embryos did not 
grow well after 2dpf. The timepoint is coincidently link to the formation of cardiac oedema at 
2dpf which may result in heart failure and slow circulation. More importantly, the RARγ 
agonist treated embryos have very slow circulation at 4dpf and finally, the oil red o staining 
show no staining of fat indicating that the cascade sequences of cardiac oedema may be 
responsible for halting the growth of treated embryos beyond 2dpf. However, the length of the 
embryos have been significantly different in RARγ agonist treated and control embryos since 
1dpf, there may be important changes happened before 1dpf.Therefore, cardiac oedema may be 
the primary effect of RARγ agonist on the heart formation which made the heart less fully 
functional resulting in the secondary effects followed. Changes in the head morphology and loss 
of pharyngeal arches in the RARγ agonist treated zebrafish embryos suggest the precursor cells, 
the cranial neural crest which involve in the zebrafish head skeletal structure might have been 
affected by the treatment.  
 RA has the teratogenic effects when the excessive level of RA is applied to the 
developing embryos. The pregnant women who were accidently exposed to the retinoid during 
their gestation period, gave birth to the babies which had the congenital defects including head 
and heart abnormalities depending on the time and period of exposure to the retinoid (Honein et 
al., 2001). Patients who have the mutation in CYP26, the gene involved in the degradation of 
RA, genito-anal and lower limbs defect (Fukami et al., 2010). The patients’ plasma RA level is 
higher than normal range (Fukami et al., 2010). These birth defects are known as posterior 
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regression syndrome (PRS). Interestingly, the parents of some PRS patients carry mutation in 
HOXD13, the gene which involve in posterior body part formation (Fukami et al., 2010). The 
patients with CYP26B1 mutation, have the craniofacial abnormalities (Laue et al., 2011). 
Feeding retinoid to the pregnant mice also give the embryos with PRS including regressed tail 
formation and ano-rectal defect (Padmanabhan 1998).  Cyp26 mutant mice also has posterior 
regression including tail as well as shorter forelimbs (Sakai et al., 2001).The zebrafish giraffe 
mutant (gir), which carry the mutation in cyp26a1, also shows the similar phenotypes to the 
RARγ agonist treated zebrafish embryos, which are shorter anterior-posterior axis, lack of 
pectoral fin, cardiac oedema, abnormal head morphology and venous dilation (Emoto et al., 
2005). Therefore, the phenotypes caused by RARγ agonist treatment to the zebrafish embryos 
are similar to those caused by RA in human, mice and zebrafish. Hence, these results confirm 
RARγ agonist worked through the similar mechanism of RA treatment.  
RA treatment causes the changes in the Wnt and Hox genes expressions. Formation of 
posterior body part formation needs the continuous supply of cells from pre somitic mesoderm 
(PSM) and treatment with RA causes the down regulation of Wnt cytokine mRNA expression 
in mice embryos (Shum et al., 1999). Moreover, RA treatment in mouse embryonic 
development causes the changes in Hox genes expression patterns (Kessel and Gruss 1991). In 
zebrafish, RA treatment interrupt the cell regulatory loop signalling in mesodermal progenitor 
niche (Martin and Kimelman 2010). No tail (ntl), which is orthologous to Brachurary in 
mammalian, is down-regulated at mRNA level after treatment with retinoic acid. Moreover, no 
tail (ntl) mutant or morpholino  has shorter trunk and tail formation (Martin and Kimelman 
2008).Therefore, treating the zebrafish embryos with the synthetic retinoid, RARγ agonist, 
which is supposed to be working through RAR also caused the embryonic teratogenic effects. 
Hox family is well known target of RA and their expression patterns are tightly regulated by the 
concentration of RA level. Therefore, treating with exogenic retinoic acid is related to increased 
or decreased expression of hox genes which are important for body axis specification (Koop et 
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al., 2010). Interestingly, overexpression of hox5b expression in the zebrafish embryo produced 
the similar phenotypes caused by RA (Waxman and Yelon 2009).  
` Although there was no certainty that RARγ agonist specifically bound to the zebrafish 
rarga and rargb, the dramatic changes were found in the tissues or organs of RARγ agonist 
treated zebrafish embryos where rarga and rargb expressions were reported by in-situ 
hybridisation technique (Waxman and Yelon 2007). These tissues or organs involve the tail bud 
during somitogenesis stage, unlike to raraa and rarab which expressions are present mainly in 
the somites (Hale et al., 2006). At 24hpf, the expression is found in the hindbrain, neural crest 
and tail. Although there was no obviosus change found in the brain in the RARγ agonist treated 
embryos, the treated embryos have the changes in the head morphology as well as the abnormal 
tail formation. Moreover, the pectoral fin bud which expresses the rarg at 48hpf was also 
affected by the RARγ agonist treatment. Morpholino gene knock down to rarga and rargb 
experiments also show the pharyngeal arches, pectoral fins and tail were affected(Linville et al., 
2009). Therefore, the treatment with RARγ agonist affected the tissues or organs where rarg 
express and are affected by morpholino knockdown. The most interesting in these findings is 
the tissues or organs where RA synthesizing enzyme is not present but the receptor is present. 
The distribution of retinoic is visualized in (Shimozono et al., 2013). The transgenic zebrafish 
line which use RARE-YFP promoter for RA signalling, also confirms RAR/RXR mediated RA 
signalling does not overlap with the tissues and organs where zebrafish rarga and rargb 
(Waxman and Yelon 2007; Perz-Edwards et al., 2001; Hale et al., 2006). Therefore, these 
findings suggest zebrafish rarga and rargb need to be in quiescent state for normal embryonic 
development because they are normally present in retinoic acid free zone and co-localized with 
the RA degrading enzyme, cyp26b1a ( Dobbs-McAuliffe et al. 2004).  
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Chapter 4 
The involvement of regulatory pathways and stem/progenitor cells in the 
developmental phenotype following RARγ agonist treatment; somitogenesis, 
pectoral fin formation and the neural crest 
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4.1. Introduction 
The results presented in Chapter 3 have shown that treatment with RARγ 
agonist to the zebrafish embryos was associated with a variety of phenotypic changes 
which included shorter antero-posterior axis, malformed caudal fin, and lack of pectoral 
fin and loss of pharyngeal arches. In this chapter, the possible causes which may have 
contributed to these changes were investigated, which involved the use of genetic 
analysis, immunostaining and transgenic zebrafish lines. Each of these investigations 
has been presented as subsections, including separate brief introductions to each of the 
studies performed, along with a description and discussion of all results shown. Data 
was presented in this way in order to demonstrate the progression of ideas and 
experiments. 
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4.2. Antero-posterior axis length and somite formation 
To analyse the possible causes of the observed shorter antero-posterior body axis in 
RARγ agonist treated zebrafish embryo, somite formation was examined because the somite is 
the main building block for the trunk in the vertebrate and major contributor to overall embryo 
length (Hammett and Wallace 1928). Since the somite boundaries during the embryogenesis are 
not visually clear enough to reliably analyse the number, structure and patterns of somites 
present by simple light microscopy, somites were observed using an indicator transgenic 
zebrafish line (hspGFF55B), and following in-situ hybridization for the myogenic 
differentiation marker, myo-D, which has been used as a marker for muscle differentiation in 
somites (Davis et al., 1989), and immunostaining for alpha actinin which is an actin binding 
protein found in the muscles. 
 
Retinoic Acid and Somitogenesis  
 Somites are the paired segmented mesodermal blocks which form from the pre-somitic 
mesoderm (PSM) located at the most posterior region of the developing embryo during 
segmentation period. They are formed “rhythmic clock and wavefront” mechanism and are the 
precursors of dermatomes, myotomes and sclerotomes. Each of which later differentiates into 
skin, muscles and bones respectively.  
 The genes which control the somitogenesis mechanisms are the two antagonizing genes 
expressions within the PSM and outside the PSM. Theese oscillating genes are  Wnt/Fgf and 
RA where Wnt/Fgf is mainly expressed in the PSM which RA is present in outside PSM. 
Interestingly, PSM is RA free zone and Wnt/Fgf induces Cyp26b1 in this area to prevent RA 
(Figure 1.5). 
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Figure 4.1. RA signalling during somitogenesis 
The picture is adapted from (Rhinn and Dollé 2012) and the permission to reuse this figure is 
obtained from the publisher. During somitogenesis, RA is synthesized by Raldh2 which is 
expressed in the developing somites. However, RA is prevented in the pre-somitic mesoderm 
(PSM), the stem cell zone by expression Cyp26A1 which active RA into unactive 4-hydroxy 
RA. Fgf8 expression is also present in the PSM during somitogenesis.  
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 Retinoic acid and Hox genes 
 Homeobox (Hox) genes are the evolutionarily conserved genes clusters which are 
expressed during segmentation periods of the developing embryos for the segmental identities. 
The hox genes families are normally important for anterior-posterior axis formation during 
development. Although it is not fully understood how the hox genes are regulated, it has been 
shown that hox genes are regulated by the endocrine factors such as RA, oestrogen and vitamin 
D. 
Retinoic acid response elements (RARE) locations have been reported near 5’ regions 
of Hoxa1, Hoxb1 and Hoxd4. And it has also been shown that RA directly regulate Hoxb1 
gene. Moreover, the retinoic acid receptors (RARs) expression during development is also co-
localized with Hox gene expression patterns during anteroposterior axis formation. In addition, 
the phenotypes of RAR knoc-out mices mimic Hox gene knock-out mice. Therefore, RA 
signalling plays as an important regulator for Hox gene expressions. 
The hox genes family is a well-known target of RA signalling and key regulator 
controlling formation of the body plan and segmental identity (Koop et al., 2010). Some 
hox genes are direct downstream targets of RA signalling (Pöpperl and Featherstone 
1993; Huang et al., 2002) and the RARE itself is located within the regulatory region of 
hox gene clusters (Zhang et al., 2000). Moreover, knock-out of hox genes in mice can 
show a loss of normal vertebrae in the mutant mice, resulting in the changes of body 
axis (Wellik 2007). Therefore, the two available hox gene reporter transgenic lines from 
the zTrap library at NIG, Mishima (Kawakami et al., 2010) were analysed for the 
patterns of gene expression after RARγ agonist treatment.   
Therefore, in this chapter, the patterns of hox genes expression by RARα 
agonism were analysed using two hox gene transgenic zebrafish lines which have the 
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reporter GFP expression patterns in the tail regions. Hence, the changes in the GFP 
expression patterns of hox gene transgenic zebrafish embryos will recapitulate the 
effects of RARα agonism on somite formation and hox gene expression.  
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4.2.1 Treatment of the reporter fish line, hspGFF55B, with RARγ agonist was 
associated with reduction in somite number. 
The transgenic fish line, hspGFF55B, from the zTrap library (Kawakami et al., 
2010) which has GFP expression both in somite and heart although the mapping for the 
insertion has not been done, this particular transgenic line has specific expression in 
somites and heart. The results of the RARγ agonist treatment on the transgenic line 
showed reduced number of somites in RARγ agonist treated embryo at 3dpf (Figure 
4.1). This expression pattern permitted the observation of a reduced number of somites 
in the RARγ agonist treated reporter fish line at 3dpf compared with reporter fish 
treated with carrier alone (controls) (Figure 4.1).  Hence, the number of somite present 
in RARγ agonist treated embryos at 3dpf was determined to be 5 fewer in treated 
embryos than the 30 somites seen in control embryo at the same stage, which is the 
normal number of somites formed in zebrafish during embryogenesis (Stickney et al., 
2000) 
The reduced number of somite was further confirmed by α actinin antibody 
staining for myocytes in somite. Alpha-actinin is the protein which is important for z-
band microfilament function and antibody staining to this protein has been used as the 
marker of functional myocyte for very long time (Sugita et al., 1974). Since somite 
differentiates into myotome and sclerotome (Duband et al., 1987), this antibody 
staining was used to visualize the number of somites formed in RARγ agonist treated 
and control embryos. The results show the agreement with the previous finding in 
RARγ agonist treated embryos which is lesser somite number than that of control 
embryos at 3dpf (Figure 4.2).  
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Figure 4.2. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with a reduction in somite formation.  
A representative fluorescence microscopy picture showing the left lateral view of RARγ agonist 
(10nM) treated (10nM) and control hspGFF55B transgenic zebrafish embryos at 3dpf where the 
somites are indicated by GFP expression. There were 5 fewer somites present in the RARγ 
agonist (10nM) treated embryos (25 somites) compared to the control embryos (30 somites), but 
there was no discernible difference in the size of the individual somite present, as shown by 
counting from anterior somites 1-10. These differences were seen in very case of RARγ agonist 
(10nM) treated versus control embryos. Scale bars represent 250µm. (n=3 independent 
experiments) 
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Figure 4.3. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was 
associated with a reduction in somite formation confirmed by α actinin staining.  
Representative fluorescence microscopy pictures of α actinin immunolocalisation in 
RARγ agonist (10nM) treated and control AB strain zebrafish embryos at 3dpf. No 
discernable differences in immunopositivity were seen. An identically reduced number 
of somites as that seen in the RARγ agonist (10nM) treated embryos immunostained for 
α actinin. Scale bars represent 250µm. Immunostaining for α actinin was performed in 
14 control embryos and 14 RARγ agonist (10nM) treated embryos.  
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4.2.2. Treatment of embryonic zebrafish with RARγ agonist was associated with weaker 
myo-D expression at 22hpf.  
To analyse the effects of RARγ agonist treatment on muscle differentiation patterns, the 
RARγ agonist treated and control embryos were stained for myo-D gene by in-situ 
hybridisation at 22hpf. The results showed the weaker expressions pattern of the staining in the 
RARγ agonist treated embryos which were harvested at 22hpf (Figure 4.3). The staining 
strength in the tails of both RARγ agonist treated and control embryos  seems the same but the 
anterior part of treated embryos have weaker staining compared to that of control embryos.  
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Figure 4.4. Treatment of embryonic zebrafish with a RARγ agonist (10nM) was associated 
with a reduction in myoD expression.  
Representative bright field pictures of in situ hybridisation for myoD expression in the RARγ 
agonist (10nM) (10nM) treated and control AB strain zebrafish embryos at 22 hours post 
fertilisation (hpf), where a slightly reduced signal was observed in somitic myoD expression in 
the RARγ agonist (10nM) treated embryos. Scale bars represent 0.5mm. myoD was determined 
in 14 RARγ agonist (10nM) treated embryos versus 13 control embryos. 
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4.2.3. Treatment of embryonic zebrafish with RARγ agonist was associated with 
reduced GFP expression in hoxc11a transgenic line created by gene-trap method. 
After observation of reduced number of somites in the RARγ agonist treated 
embryos than control embryos, the positions of missing somites were investigated using 
RARγ agonist treated hoxc11a transgenic line. Precise expression of hox-gene family 
during the body axis formation is necessary for normal antero-posterior axis in 
vertebrate (Wellik 2007). Hoxc11 expression can be found in the posterior region of 
developing mice embryos (Hostikka and Capecchi 1998) and Hoxc-cluster homozygous 
knock–out mice shows transformation of caudal vertebra to lumbar vertebra resulting in 
loss of caudal vertebra (Suemori and Noguchi 2000). Here, our results also showed 
treatment with RARγ agonist to the hoxc11a gene trap line causes reduced expression 
of hoxc11a from 1dpf to 5dpf (Figure 4.4). In 1dpf, hoxc11a expression can be seen in 
the most posterior region of the developing embryo and the length of GFP expression in 
RARγ agonist treated embryo was significantly lower than that of control embryos. 
After hatching from the chorion at 2dpf, the area covered by the GFP expression in the 
posterior region is clearly visible. In the RARγ agonist treated embryo, the percentage 
of GFP expressing length to the whole body length never exceeded more than 30% 
from 2dpf to 5dpf while the GFP coverage in the control embryo was more than 40% at 
2dpf and more than 50% from 3dpf to 5dpf. These results indicate hoxc11a-GFP 
expression moved from posterior to anterior end throughout the development in the 
control embryos whilst that anterior progression was halted in the RARγ agonist treated 
embryos.  
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Figure 4.5. Differential patterns of hoxc11a expression in transgenic reporter zebrafish 
embryos demonstrated that the reduced axial length of RARγ agonist (10nM) treated embryos 
was associated with loss of their most posterior regions.  
(A) A graph shows the difference in length of GFP expression between RARγ agonist (10nM) 
treated and control transgenic lines at 1dpf. The length of GFP expression in the tail region of 
RARγ agonist (10nM) was significantly reduced compared to the control. (B) A graph 
compares the percentage of the body length which had GFP between RARγ agonist (10nM) 
treated and control embryos from 2dpf to 5dpf. The percentage of GFP length did not 
significantly increase in the RARγ agonist (10nM) treated embryos compared to the control 
embryos throughout the development stage. (C) A representative fluorescence microscopy 
picture showing GFP expression in the hspGFF155A transgenic zebrafish reported line for 
hoxc11a expression at 3dpf, where a similar pattern of expression was seen in the RARγ agonist 
(10nM) treated and control embryos. Scale bar represents 1mm. (n=3 independent experiments) 
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4.2.4. Treatment of embryonic zebrafish with RARγ agonist was associated with the 
complete loss of gene expression in hoxb13a transgenic line.  
Another hox gene line was also analysed to see the effects of hox gene in body axis 
formation in RARγ agonist treated embryos. The transgenic line was used from zTrap library 
(Kawakami et al., 2010) created by enhancer trap line method. The GFP-sequence was inserted 
in hoxb13a of zebrafish genome. The GFP expression starts to be seen in the most caudal area 
of the embryos at 1dpf. In the mice embryos, the hoxb13 expression can be in the tail-bud area 
around E9 stage (Zeltser et al., 1996). Interestingly, the similar hoxb13 expression is also found 
in the developing tail of axolotl as well as in the regenerating tail after amputation (Carlson et 
al., 2001). Interestingly, there is no report of complete gene knock out for hoxb13 but targeted 
mutations in mice hoxb13 gene causes overgrowth of tail vertebra and spinal cord (Economides 
et al., 2003). The results of the RARγ agonist treatment on hox13a line showed the complete 
loss of GFP expression in RARγ agonist treated embryos in the tail and anal region from 1dpf 
to 5dpf (Figure 4.5).  
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Figure 4.6. Differential patterns of hoxb13a expression in transgenic reporter zebrafish 
embryos demonstrated that the reduced axial length of RARγ agonist (10nM) treated embryos 
was associated with loss of their most posterior regions.  
Representative fluorescence microscopy pictures showing GFP expression in the 
hspGFFDMC28B transgenic zebrafish reporter line for hoxb13a expression from 1dpf to 3dpf. 
In contrast to the control embryos, RARγ agonist (10nM) treated embryo exhibited a complete 
loss of GFP expression in the tail, as well as in the anal region. Scale bars represent 250µm. 
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4.2.5. hoxb13a GFP expression and caudal fin formation were rescued by wash out 
of the RARγ agonist or additional treatment with RARγ antagonist.  
 The previous results showed the complete loss of GFP expression in RARγ 
agonist treated hoxb13a transgenic reporter zebrafish embryos at 3dpf. Moreover, the 
data also suggested the loss of GFP expression was in the most posterior part of the 
embryos including the caudal fin plus loss of posterior tissues and somites. Zebrafish 
has been used as a good model for regeneration of various organs and tissues including 
the caudal fin (Kawakami et al., 2004; Porcellini 2009). In addition, hox gene family 
are involved in caudal fin regeneration (Carlson et al., 2001; Thummel et al., 2007). 
Therefore, the follow-up experiments were done to test a hypothesis, if the loss of 
posterior tissues in RARγ agonist treated zebrafish embryos was mainly due to loss of 
hoxb13a effect by RARγ agonist treatment, the removal of RARγ agonist from the 
zebrafish embryos just before the time-point of hoxb13a expression should rescue the 
gene expression. Moreover, if hoxb13a expression in zebrafish is implicated in the 
caudal fin regeneration like in axolotl (Carlson et al., 2001), the re-expression of 
hoxb13a  should be associated with fin regeneration.  
 The results show the re-repression of hoxb13a was observed at 5dpf in the 
reporter transgenic zebrafish embryos when they were treated with RARγ agonist from 
4hpf to 23hpf which is the time point that hoxb13a starts to express in the most 
posterior region of the tail, followed by the washing out of RARγ agonist, replaced with 
the control media or additionally treated with the RARγ antagonist (Figure 4.6). The 
GFP expression was not initially observed in the tail area until 5dpf. Initially, the GFP 
expression was observed in RARγ agonist washed out or RARγ antagonist co-added 
hoxb13a transgenic zebrafish embryos at 2dpf and 3dpf. The tiny GFP expression 
started to appear in the caudal area at 4dpf and finally, the clear expression of GFP was 
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observed at 5dpf. Therefore, the GFP re-expression of hoxb13a took approximately 3 
days. The regenerated caudal fin was also present in the hoxb13a rescued transgenic 
zebrafish embryos (Figure 4.7). Therefore, the results showed the loss of GFP 
expression in the RARγ agonist treated hoxb13a transgenic embryos was rescuable by 
the removal of RARγ agonist and the time frame period to rescue hoxb13a expression 
including the caudal fin regeneration took approximately 3 days. Interestingly, the time 
frame for the re-expression of GFP and caudal fin regeneration coincides with the time 
to regenerate the zebrafish larval fin regeneration after amputation (Kawakami et al., 
2004). Therefore, the hoxb13a expression in the zebrafish caudal fin might have an 
important role for regeneration like in the axolotl (Carlson et al., 2001).  
 The additional experiments related to the hoxb13a expression showed other 
interesting natures of the gene. The hypothesis was to test the repressive activity of 
RARγ agonist on the gene expression. The hoxb13a transgenic embryos were treated 
with RARγ agonist at 23hpf which is the time point that GFP expression started to 
appear in the tail. Interestingly, the GFP expression was observed in the RARγ agonist 
treated embryos at 2dpf although the caudal fin was not fully formed (Figure 4.8). 
Conversely, the transgenic embryos which were treated with RARγ agonist at 22hpf, 
one hour before the actual GFP expression appeared, did not show any GFP expression 
in the tail at 2dpf (Figure 4.9). Therefore, these data suggested the repressive activity of 
RARγ agonist targeted at the transcriptional level rather than the translational level of 
hoxb13a expression because treatment with RARγ agonist at 23hpf did not prevent the 
GFP expression at 2dpf.  
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Figure 4.7. The effect of a RARγ agonist (10nM) on hoxb13a was reversed by agonist 
washout or co-treatment with a RARγ antagonist. 
Representative fluorescent microscopic pictures showing GFP expression in the 
hspGFFDMC28B transgenic zebrafish reporter line for hoxb13a expression at 5dpf, in which 
the embryos were treated with RARγ agonist (10nM) at 4dpf and (A) washed out of RARγ 
agonist at 23hpf, (B) then co-treated with RARγ antagonist at 23hpf (C) no followed up 
modification.  The arrows showed the GFP re-expression in the caudal fin area. Scale bars 
represent 250µm. (n=4 independent experiments) 
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Figure 4.8. The effect of a RARγ agonist (10nM) on caudal fin outgrowth was reversed by 
agonist washout or co-treatment with a RARγ antagonist. 
The graph shows the comparative length of caudal fin in the RARγ agonist (10nM) treated 
embryos versus the wash out or RARγ antagonist co-treated embryos at 5dpf. Data are shown as 
means +/- SD, pooled from 4 independent experiments. 
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Figure 4.9. Treatment with a RARγ agonist (10nM) to the hoxb13a reporter transgenic line 
a23hpf failed to prevent the GFP expression at 2dpf. 
Representative fluorescent microscopic pictures showing GFP expression in the 
hspGFFDMC28B transgenic zebrafish reporter line for hoxb13a expression in the caudal area 
(A) at 2dpf in which the embryos were treated with RARγ agonist (10nM) at 23hpf (B) at 2hpf 
in which the embryos were treated with control media at 23hpf and (C) at 23 hpf which was the 
first time point of GFP expression in the caudal area. The arrows showed the GFP expression in 
the caudal fin area. Scale bars represent 250µm. (n=2 independent experiments) 
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Figure 4.10. Treatment with a RARγ agonist (10nM) to the hoxb13a reporter transgenic 
reporter zebrafish embryos at 22hpf blocked the GFP expression at 2dpf. 
Representative fluorescent microscopic pictures show the hspGFFDMC28B transgenic 
zebrafish embryos at 2dpf. The transgenic embryo which was treated with RARγ agonist 
(10nM) at 22hpf did not show any GFP expression in the tail region at 2dpf (A) while the 
control embryo showed the GFP expression in the tail region at 2dpf (B) (arrowed). Scale bars 
represent 250µm. (n=3 independent experiments) 
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4.2.5 Discussion 
4.2.5.1 Loss of hoxc11a and hoxb13a indicated the missing caudal somites in RARγ agonist 
treated zebrafish embryos.  
The findings above have simply driven to summarise hox-genes are responsible for the 
shorter body axis. However, it is not the conclusive answer because the loss of fat particles in 
RARγ agonist treated embryos has been reported in Chapter 3. The role of nutritional factors to 
the growth cannot be ignored and eventually, it is safer to conclude the short antero-posterior 
axis formation may be multi-factorial.  
Short antero-posterior axis length in treatment is a common associated phenotype. All 
the accessible papers of drug toxicity on early zebrafish development published from 1997 until 
nowadays point out the shorter body axis regardless to the type of drugs. Therefore, it is 
impossible to rule out that the shortening of antero-posterior axis in this project is simply 
because of toxicity of the drug which may even have nothing to do with the receptor although 
the solution has the right pH.    
However, there was a strong relationship between the changes of hox-gene expressions 
and the shorter antero-posterior axis in RARγ agonist treated zebrafish embryos. RARγ agonist 
treatment directly might have caused the reduced hox-gene expressions resulting in shorter 
antero-posterior axis. On the other hand, RARγ agonist might have interacted with another 
molecular signalling pathways resulting in loss of the posterior somite formation, and as the 
consequence, there are no somite to express hox genes. Nevertheless, both possibilities confirm 
the missing somite in RARγ agonist treated zebrafish embryos were from the caudal region.  
Over 350 papers published about hox genes study in zebrafish show hox genes were 
impossible to visualize or clone unless somite are present because the segmentation patterns 
formation simply depends on somites. This information indicates the possibility about loss of 
hoxc11a and hoxb13a was due to lack of somite to express these genes. This hypothesis 
explains hoxc11a expression in the RARγ agonist treated embryos was never more than 30% of 
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total body length because there was no more somite forming at the most posterior region and 
loss of hoxb13a in the most posterior region of treated embryos was because of the somite 
which express hoxb13a  never formed in the RARγ agonist treated embryos. Therefore, the loss 
hox gene expressions are secondary effects of somitogenesis which lead to investigate the 
signalling involved in somitogenesis which is wnt signalling (Gibb et al., 2009; Martin and 
Kimelman 2008; Martin and Kimelman 2010).  
However, it is difficult to ignore the facts that RARE (retinoic acid response element) is 
located in the regulatory region of hox gene clusters (Zhang et al., 2000; Pöpperl and 
Featherstone 1993; Huang et al., 2002) and the chemical used in this project itself has been 
reported for working through the retinoic acid receptor in mammalian cell line (Hughes et al., 
2006). More importantly, there is crucial evidence present in hoxb13a results (Figure 4.5) which 
shows there is an extra-somitic expression of hoxb13a gene in the anal fin area which is distant 
from the somite. This odd finding is purely contradicting the second hypothesis of somite are 
responsible for loss of gene expression. The hoxb13a expression in the protodeum is not ectopic 
or non-specific expression of the enhancer trap line because this hoxb13 gene expression 
pattern has been studied and its expression in hindgut and urogenital area of mice is also 
reported (Zeltser et al., 1996). Interestingly, this protodeum is ectodermal derived, not 
mesodermal. Therefore, the hypothesis of somite-dependent hox gene expression is 
contradictory to this finding and it is also pointing loss of hox gene is direct effect of retinoic 
acid gamma agonist drug. These findings agree with the discussion of caudal regression 
syndrome symptoms and gene mutation found in human patients (Chapter 3). Therefore, the 
loss of hox genes may partially direct effect and partially indirect effect depending on the 
tissues or organs. However, this conclusion raises another question. 
The experiments conducted in zebrafish so far show RA treated zebrafish has increased 
hox gene expressions and treatment with DEAB(retinoic acid inhibitor) shows loss of hox gene 
expressions according to the in-situ hybridisation techniques (Ishioka et al., 2011; Maves and 
Kimmel 2005) and qtPCR results show mRNA of hox genes increase three to six folds after 
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treatment with RA (Oliveira et al., 2013). These papers are clearly contradicting the results of 
hoxc11a and hoxb13a which have the reduced or loss of gene expression.  
 At last, the experiments on the re-expression of hoxb13a indicate the repressive activity 
of RARγ agonist on hoxb13a expression was temporary at transcriptional level and the gene 
expression can be restored after the removal of RARγ agonist. Moreover, the results also 
suggested the repressive activity of RARγ agonist on stem/progenitor cells which are 
responsible for the somite formation, was transient and the stem/progenitor cells niches were 
not permanently repressed. On the other hand, the results also indicated that the ligand free 
RARγ expression was important for the somite formation as well as in caudal fin formation. 
Interestingly, a very recently published paper (Janesick et al., 2014) also showed the ligand free 
RARγ expression is required for vertebrate axis formation using Xenopus as model organism.  
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4.3. Introduction for loss of pectoral fin 
Another phenotype found in the RARγ agonist treated zebrafish embryo is the loss of 
pectoral fin. As mentioned in the previous chapter, the treatment of RARγ agonist was 
associated with loss of pectoral fin at 3dpf. Therefore, in this chapter, the possible causes and 
mechanisms involved in the pectoral fin formation of RARγ agonist treated embryo is dissected. 
Since RARγ agonist is related to the retinoic acid signalling, the involvement of RA is first 
investigated. As mentioned in (Gibert et al., 2006) paper, the pectoral fin formation starts with 
the raldh1a2, the gene responsible for the conversion of retinaldehyde to RA, expression in the 
somite region of 2 to 6. Localized expression of this enzyme synthesizes RA which can be 
visualized in the respective region (Shimozono et al., 2013). The synthesized RA induces the 
tbx5a which is the transcription factor responsible for heart and pectoral fin formation. Nls 
(neckless) mutant zebrafish which has mutation in raldh1a2 g (Grandel et al., 2002) or RA 
synthesis inhibitor, DEAB (diethylaminobenzyldehyde), treated embryo show lack of pectoral 
fin formation including loss of tbx5a expression (Grandel and Brand 2011) as the result of 
failure to induce tbx5a by RA. Moreover, tbx5a mutation causes loss of pectoral fin formation 
in the mutant line called heart string in which tbx5a is mutated (Garrity et al., 2002). Therefore, 
to find out why RARγ agonist treated embryos have loss of pectoral fin, the first gene to look at 
is tbx5a expression in the RARγ agonist treated embryos. It was hypothesized that the tbx5a 
gene expression might be down-regulated since high level of RA inhibits raldh1a expression by 
reducing the interaction of raldh1 promoter binding and the proteins (Elizondo et al., 2009). 
Therefore, the presence of tbx5a expression was analysed in RARγ agonist treated embryos 
which may be affected by down-regulation of raldh1a as the possible result of negative 
feedback mechanism of high level of RARγ agonist.    
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4.3.1. tbx5a expression was present in RARγ agonist treated embryos. 
Zebrafish tbx5a expression is seen from 14hpf in the lateral late mesoderm and eyes to 
4dpf  in heart, eyes and pectoral fins according to in-situ hybridization report (Albalat et al., 
2010). The expression pattern found in lateral plate mesoderm which is common progenitor for 
heart and pectoral fins and become separated from 24hpf and at 27hpf, the expression can 
clearly be seen at three different tissues, eyes, heart and pectoral fin ridge which is about to 
become the fin bud (Albalat et al., 2010). Therefore, the RARγ agonist treated and control 
embryos were fixed at 27hpf and stained for tbx5a expression. The results show both control 
and RARγ agonist treated embryos had the gene expression in heart and pectoral fin areas, but 
not in eyes (Figure 4.10).  
The presence of tbx5a transcription factor was validated using non-immuno staining 
experiments. The hypothesis was to treat the embryos with RARγ agonist during the window 
periods which have tbx5a expression. In simple terms, if the transcription factor was not 
functioning or disrupted by the treatment, the fin formation will not form even if the RARγ 
agonist was removed after certain period of treatment. Again for the time point, the 27hpf was 
chosen again because it is the transition point where the lateral plate mesoderm expression 
tbx5a starts to form the pectoral bud (Albalat et al., 2010). The results (Figure 4.11) show the 
confirmation of the presence of tbx5a in RARγ agonist treated embryos because the RARγ 
agonist treated embryos grew the pectoral fins back when the RARγ agonist media was replaced 
with control media or the same concentration of RARγ antagonist was added at 27hpf. This 
findings lead to assume the loss of pectoral fin in RARγ agonist treated embryos was nothing to 
do with tbx5a expression, and possibly the defects in outgrowth. To confirm this hypothesis, the 
results (Figure 4.11) show the wild type embryos could not grow the pectoral fins when they 
were treated with the RARγ agonist (10nM) at 27hpf. 
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Figure 4.11. Treatment of zebrafish embryos with RARγ agonist (10nM) was associated with 
no evident changes in loss of tbx5a expression in the lateral plate mesoderm. 
Representative confocal microscopy projected images of z stacks through the entire lateral 
perspective of AB strain zebrafish following tbx5a immunolocalisation. As shown, a similar 
distribution of tbx5a immunopositivity was seen in the lateral plate mesoderm and heart regions 
(both arrowed) at 27hpf in the RARγ agonist (10nM) (10nM) treated and control embryos 
following immunostaining in 10 control and 10 RARγ agonist (10nM) treated embryos. Scale 
bars represent 250µm. 
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Figure 4.12. Treatment of zebrafish embryos with a RARγ agonist (10nM) was associated 
with a reversible block in pectoral fin outgrowth 
Representative phase contrast microscopy pictures showing normal outgrowth of the pectoral 
fin in control AB strain embryos at 3dpf and the complete loss of pectoral fin outgrowth that 
was observed in RARγ agonist (10nM) treated embryos at the same time point. Pectoral fin 
outgrowth in AB strain embryos that had been treated with the RARγ agonist (10nM) at 4hpf 
was restored either by washing out the RARγ agonist (10nM) at 27hpf or adding an equal dose 
(10nM) of the RARγ antagonist at 27hpf. Conversely, pectoral fin outgrowth in control 
embryos was completely blocked when control media was replaced with the RARγ agonist 
(10nM) supplemented media at 27hpf. Scale bars represent 250µm. (n=3 independent 
experiments) 
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4.3.2. RA itself did not inhibit the pectoral fin outgrowth. 
Since the early treatment of RA to the embryos at 4hpf resulted in embryonic truncation 
at 1dpf (Chapter 3), it was impossible to access whether the pectoral fins were affected by RA 
itself although there was no report that fin formation was affected by RA. Therefore, to confirm 
whether the inhibitory effect of RARγ agonist (10nM) was working through the gamma 
receptor, the embryos were treated with 10nM retinoic acid at 27hpf. The results (Figure 4.12) 
showed that the RA did not inhibit the pectoral fin outgrowth even the concentration was 
increased to 20nM.  However, the fin length and orientation were not the same as control 
embryos of 3dpf. 
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Figure 4.13. Treatment of zebrafish embryos with a RA was associated with no evidence for 
loss of pectoral fin. 
Representative phase contrast microscopy pictures showing outgrowth of the pectoral fin in RA 
treated zebrafish embryos at 4dpf. Both zebrafish embryos which were treated with RA (10nM) 
and RA (20nM) at 27hpf had the pectoral fin outgrowth at 4dpf. Therefore, RA itself did not 
inhibit the pectoral fin outgrowth as seen in RARγ agonist treated zebrafish embryos following 
the observation in 30 RA treated embryos and 30 control embryos. Scale bars represent 250µm. 
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4.3.3. Discussion for pectoral fin. 
Based on the results regarding to the pectoral fin formation in RARγ agonist treated 
embryo, there are three interesting points which need to be discussed. They are tbx5a 
expression pattern, reversible effects of RARγ agonist on pectoral fin outgrowth and the 
different effect of RA. 
The first of the findings, tbx5a expression somehow shows it had not been affected and 
its existence was also confirmed by the wash-out experiments. However, this finding brings up 
another interesting thing for discussion which is not directly related to the RARγ agonist 
treatment on pectoral fin formation. Indeed, the immunostaining pattern showed lack of staining 
in the eyes which participation has been reported at the same time point by in situ hybridisation 
(Albalat et al., 2010). This is rather interesting indication that non-overlapping finding between 
two different techniques, one detects the mRNA level and the other is for protein. In fact, this 
finding is more than a coincident because a zebrafish mutant line, known as “heart-string” 
which has premature mutation in tbx5a gene, shows lack of pectoral fin bud formation and 
severe heart oedema but, normal eye formation (Garrity et al., 2002). In addition, translational 
blocking morpholino injection also indicates lack of pectoral fin, cardiac oedema but normal 
eye formation again(Garrity et al., 2002), indicating the mRNA in the eyes are not translated 
into the protein. These findings indicate the different translational behaviours of tbx5a.  
This pattern of gene expression does not only apply to the zebrafish, the 8 and 9 days 
old mice embryos also show the tbx5 expression in the optic vesicle (Chapman et al., 1996). 
Again, stage 14 chick embryos also show tbx5 expression in the eye using in-situ hybridisation 
(Ohuchi et al., 1998). The similar expression in the eye of Xenopus also has been reported 
(Horb and Thomsen 1999). Tbx5 mutant mice also show the birth defect of heart and limb 
formation in both homo and heterozygous embryos, but no reported defect to eyes (Bruneau et 
al., 2001).   These findings are consistent with human tbx5 mutation, Holt-Oram syndrome, 
presented by cardiac and hands defects, but not eyes (Muru et al., 2011).  
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There is a small chance to argue about miRNA which is well-known post 
transcriptional regulatory mechanism, which may silence the mRNA in the eyes. Therefore, the 
gene expression in the eye may be the mRNAs which are about to be degraded by miRNA and 
the in-situ staining in the eyes are possibly the results of catching the tiny window period of 
mRNA. Nevertheless, this finding brings up a question which is far more important than ectopic 
expression pattern. In-situ technique has been using as a tool for genetics and developmental 
study since 1970s. In most scenarios where the antibodies are difficult to apply, especially in 
zebrafish, this technique has been using as the study for relative level of gene expression for 
decades. Therefore, the question is “how reliable is this technique as an indicator of gene 
expression if an organism itself has certain post-transcriptional mechanisms?”  This finding also 
rings the bell for mRNA injection. RNA injection is widely used as rescue experiments for 
mutant embryos or morpholino injected embryos. How can the differences be told between 
100% rescued embryos and partially rescued embryos? 
Both tbx5a immunohistochemistry and wash-out experiments confirmed the RARγ 
agonist treatment did not interrupt with it and it also shows the interaction came from the down-
stream genes of tbx5a and the whole effect is reversible. So, what are the down-stream genes 
and how? Using morphilonos and in-situ hybridization, fgf8 and fgf10 are proposed as the 
downstream genes of tbx5a (Ng et al., 2002). Another fgf family,fgf24, is also a proposed 
candidate for tbx5a downstream using a fgf24 mutant line and in-situ hybridisation (Fischer 
2003). Another non-fgf  genes which seems to be downstream of tbx5a are sall4 (Harvey and 
Logan 2006), blimp-1 (Lee and Roy 2006), prdm1 (Mercader et al., 2006), beta-CaMK-II 
(Rothschild et al., 2009) and ndrg4 (Qu et al., 2008). Therefore, RARγ agonist might have 
interacted one or more downstream genes of tbx5a mentioned above.  
Another group of genes which is reported to be involved in pectoral fin formation is 
hox family. Regardless to whether this family is upstream or downstream of tbx5a; their 
expression is down-regulated by RARγ agonist treatment according to the previous findings on 
hoxc11a and hoxb13a. Using in-situ hybridization, hoax (Géraudie and Borday Birraux 2003; 
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Metscher et al., n.d.), hoxb (Waxman et al., 2008) and hoxd (Sakamoto et al., 2009; Neumann 
et al., 1999) are the genes expressed in the developing pectoral fins. Although there is no 
evidence that loss of any of hox genes mentioned above are responsible for loss of pectoral fin 
outgrowth, this group of gene expression in pectoral fin is an obvious clue for the relationship 
between hox genes and RARγ agonist treatment.  
The finding of RA on pectoral fin is very different to the effects of RARγ agonist on 
pectoral fin. In fact, the arguable point about RA is the stability. Because of the structure of RA 
compound, it is very sensitive to light and temperature and oxidized. Although the plates were 
wrapped in foil, the temperature may have involved in oxidation of the RA resulting in reduced 
efficiency within hours after treatment. This no longer effective RA may not have prevented the 
pectoral fin outgrowth. Therefore, the difference in the chemical properties between RA and 
RARγ agonist may have resulted in opposite finding. 
The dilemma in this project is the effects of RARγ agonist were expected to be the 
same as RA in most cases. Since there is no proof for the specificity of RARγ agonist, it is not 
very difficult to be surprised for the opposite effects between RA and RARγ agonist. So far, 
there is no paper showing the inhibitory effect of RA on pectoral fin outgrowth. In fact, RA 
itself has been used to rescue the pectoral fin formation in pectoral fin mutant embryos 
(Begemann et al., 2001; Grandel and Brand 2011). More interestingly, apc morphant embryos 
which have the pectoral fin buds that fails to growth can be rescued by adding of RA (Nadauld 
et al., 2004). These evidences indicate RA has promotional effect on pectoral fin formation 
rather than inhibitory effect. Even so, there is still an arguable point which is either RA or 
RARγ agonist may have other effects which do not involve the conventional ligand-receptor 
response.   
Therefore, what about a mutant zebrafish which intrinsic RA is always high? 
Interestingly, a zebrafish mutant line called giraffe, which has RA degrading enzyme 
cyp26a1mutation, shows smaller pectoral fin outgrowth (Emoto et al., 2005). Therefore, 
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pectoral fin formation in RA treated zebrafish might be the results of quick degradation of RA 
due to temperature and oxidation. 
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4.4. Introduction for loss of cranial structures 
Another phenotype of RARγ agonist treated zebrafish embryos is loss of pharyngeal 
arches, which suggests the cells differentiate into pharyngeal arches, might not have formed. 
The pharyngeal arches originate from cranial neural crest (Kague et al., 2012). Since the cranial 
neural crest can differentiates into other cranial structures such as cranial bones, cartilages and 
nerves (Dutton et al., 2001; Rodrigues et al., 2012), the cranial bone formation and lateral line 
ganglions were examined whether they were affected by RARγ agonist treatment. In addition, 
the changes in neural crest cell formation between RARγ agonist treated and a control embryo 
was also examined.  
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4.4.1. Treatment with RARγ agonist was associated with loss of almost all cranial bones. 
The bone staining results of both calcein and alizarin red show lack of cranial bones in 
RARγ agonist treated embryos at 5dpf. Interestingly, all the neural crest derived bones were not 
lost. According to lineage tracing experiment on cranial neural crest, all the named bones 
mentioned in the results are neural crest derived including cleithrum (Kague et al., 2012). 
Therefore, all the neural crest derived bones except ceratobranchial5 bone and cleithrum were 
lost in RARγ agonist treated embryo (Figure 4.13). Again, all the bones mentioned in the results 
are endochondrial bone except cleithrum which is dermal bone (Kague et al., 2012). In the 
RARγ agonist treated embryos, only the most posterior part of ceratobranchial5 bone which is 
adjacent to cleithrum bone, was still present. 
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Figure 4.13. Treatment of zebrafish embryos with a RARγ agonist (10nM) was associated 
with loss of cranial bones.  
Representative confocal and fluorescent microscopy pictures showing dorsal view calcein bone 
staining in RARγ agonist (10nM) treated and control AB strain embryos at 5dpf. Representative 
bright field microscopy pictures of Alizarin Red S stained AB strain embryos showing that all 
of the cranial bones were absent in RARγ agonist (10nM) treated embryos at 5dpf except for the 
most posterior part of the cerebrobranchial 5 bone and the cleithrum bones. Scale bars represent 
250µm. (n=3 independent experiments) max=maxillary bone, hm= hyomandibular bone, 
op=opercle bone, cb5=cerebrobranchial bone 5 and cl= cleithrum bone. 
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4.4.2. Treatment with RARγ agonist was associated with loss of anterior lateral line 
ganglions. 
The previous findings on the head morphology suggested the neural crests were 
affected. Therefore, in this experiment, the RARγ agonist was used to treat on the transgenic 
line from zTrap library (Kawakami et al., 2010) which has the GFP-expression in lateral line 
and its ganglions. The gene mapping shows the HGn39D sequence was inserted within a locus 
coding for contactin-associated protein-like2 (Cntnap2b) and the protein is expressed in the 
lateral line and its ganglions (Pujol-Martí et al., 2012). Lateral line system is found in aquatic 
animals, is a part of peripheral sensory nervous system and derived from neural crest (Collazo 
et al., 1994). Therefore, the hypothesis was the lateral system will be affected if the neural crest 
cells were disrupted by RARγ agonist treatment.   
The results of rarg-agonist to HGn39D show loss of anterior lateral line ganglion in 
RARγ agonist treated embryos (Figure 4.14). At 1dpf, RARγ agonist treated and control 
embryos had visible posterior lateral line ganglions. Small GFP expression in anterior lateral 
line ganglion in control embryos was also found at 1dpf. However, in the RARγ agonist treated 
embryos, the anterior lateral line ganglion was not present until 5dpf although they had the 
lateral line and posterior ganglion. Therefore, this results show loss of anterior lateral line 
ganglion in RARγ agonist treated embryos.  
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Figure 4.15.  Treatment of zebrafish embryos with a RARγ agonist (10nM) was associated 
with loss of anterior lateral line ganglions. 
Representative fluorescent microscopy pictures of the transgenic zebrafish HGn39D reporter 
line, demonstrating the specific loss of GFP signal in the anterior lateral line ganglia (arrowed) 
of RARγ agonist (10nM) treated embryos only at from 1dpf to 5dpf, but not in the posterior 
lateral line ganglia PLG (arrowed) or the lateral line (arrowed) itself, all of which were evident 
in control embryos at the same stage. Scale bars represent 250µm. (n=3 independent 
experiments) ALG= anterior laterline ganglion, PLG= posterior lateraline ganglion, NM= 
neuromast 
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Figure 4.16.  Treatment of zebrafish embryos with a RARγ agonist (10nM) was associated 
with loss of anterior cranial structures which were anterior to the posterior end of otic 
vesicle. 
A diagram demonstrates the area of cranial structures which were affected by RARγ agonist 
(10nM) treatment. The highlighted area shows the areas which were anterior to the posterior 
margin of otic vesicle and the structures in this area were affected by RARγ agonist (10nM) 
treatment. These structures include cranial bones, anterior lateral line ganglions and eyes.   
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4.4.3. Lateral line function was still present in RARγ agonist treated embryos. 
The previous results show the anterior lateral line ganglions were diminished in RARγ 
agonist treated embryos but they still had the posterior and the rest of lateral line. One of the 
functions of lateral line system is burst swimming response or escape response where the lateral 
line mediates very fast response to sudden mechanical stimuli (McHenry et al., 2009). 
Therefore, the functional experiment for lateral line system was checked using touch- response 
test. Both the RARγ agonist treated and control embryos showed the response to the stimuli 
although the treated embryos had shorter period of swimming response time (Figure 4.16). This 
result shows the RARγ agonist treated embryos still had functional lateral line system although 
the anterior lateral line ganglion was diminished.  
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Figure 4.17.  Treatment of zebrafish embryos with a RARγ agonist (10nM) was associated 
with no evidence of loss of swimming response. 
Representative videos show the swimming response of control and RARγ agonist (10nM) 
treated embryos at 2dpf. The embryos were stimulated by a hair at the trunk region to see the 
burst swimming response and RARγ agonist (10nM) treated and control embryos showed the 
positive response although the RARγ agonist (10nM) treated embryos had weaker responding 
period. RARγ agonist (10nM) treated and control embryos had burst swimming response at 
2dpf. (n=3 independent experiments) 
  
RARγ agonist  Control 
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4.4.4. Treatment with RARγ agonist was associated with reduced sox9 expression 
at 60hpf. 
The final jigsaw part of these series of experiments is to find out whether the 
cranial neural crests were actually affected by RARγ agonist treatment. To check the 
pattern of expression in RARγ agonist treated embryos, sox9 antibody was used as a 
marker for neural crest (Li et al., 2002). Sox9 expression can be found in neural crest 
cells, otic vesicle and pharyngeal arches (Rau et al., 2006). Since both rarg receptors in 
zebrafish have different time point of expression and sox9 expression starts to be seen 
in neural crest from early segmentation period (Li et al., 2002), the neural crest 
formation in RARγ agonist treated zebrafish was analyzed at different time points to 
identify the possible receptor subtype affected by the treatment. The rarga expression 
starts at 24hpf (Hale et al., 2006) and the rargb expression can be seen as early as 10-
somite stage (Waxman and Yelon 2007). Therefore, the time point 22hpf was chosen to 
analyse the pattern of neural crest expression in the treated embryos because if the 
RARγ agonist was working through the rargb, there may be changes in neural crest 
expression pattern in the treated embryos at 22hpf which is the time point just before 
rarga starts to express at 24hpf.  
The immunostaining results show there was no difference in the expression 
pattern of neural crest at 22hpf in RARγ agonist treated and control embryos (Figure 
4.17).  The next time point chosen to check the pattern of neural crest expression is 
60hpf because the previous results show the neural crest derivatives in RARγ agonist 
treated embryos were already lost at 3dpf (after 72hpf). The staining results show the 
RARγ agonist treated embryos did not have the staining whereas the control embryos 
had the staining in the neural crest cells, pharyngeal arches and otic vesicle (Figure 
4.17). The next experiment was to narrow down the time point and the staining from 
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48hpf time point showed there was no much difference between treated and control 
embryos.  
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Figure 4.18. Treatment of zebrafish embryos with a RARγ agonist (10nM) was associated 
with loss of sox9 immunopositive cranial neural crest stem/progenitor cells.  
Representative confocal microscopy projected pictures of z stacks through the entire lateral 
perspective of AB strain zebrafish following sox9 immunolocalisation are shown. A similar 
number of sox9 immunopositive pictures were seen in RARγ agonist (10nM) and control 
embryos at 25hpf. However, reduced numbers of sox9 immunopositive cells were observed in 
the RARγ 
Whitney U test). Sox9 immunopositivity was observed in the developing pharyngeal arches (pa) 
was observed in control embryos only at 60hpf (arrowed), but were not seen in RARγ agonist 
(10nM) treated embryos. Scale bars represent 250µm. Data are shown as mean +/-SD, pooled 
from following immunostaining and score of 3 control and 6 RARγ agonist (10nM) treated 
embryos. 
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4.4.5. The acridine orange staining showed no difference in RARγ agonist treated and 
control embryos. 
Sox9 immunostaining shows loss of staining in RARγ agonist treated embryos at 60hpf. 
Therefore, the next question to answer is “what happened to the neural crest in RARγ agonist 
treated embryos?” In previous results, it was suggested the loss of neural crest occurred 
between 48hpf and 60hpf. Therefore, the easiest and cheapest way to start to find out was to 
check the cell apoptosis using acridine orange. However, the results show there was no 
difference between rarg-agonist treated and control embryos at 2dpf (Figure 4.18).  
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Figure 4.19. Treatment of zebrafish embryos with a RARγ agonist (10nM) was associated 
with no evidence of apoptosis in the head area at 2dpf.  
The representative pictures show acridine orange staining in RARγ agonist (10nM) treated and 
control embryos at 2dpf. There was no evidence of staining in the cranial neural crest area of 
RARγ agonist (10nM) treated and control embryos at 2dpf. Scale bars represent 250µm. (n=2 
independent experiments) 
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4.4.6. Discussion for neural crest 
These findings confirm the loss of cranial bones had contributed to the changes in the 
head morphology and loss of pharyngeal arches in the RARγ agonist treated embryos. Rather 
interesting finding in this experiment was the pattern of cranial bone loss. Although almost all 
the neural crest derived bones were lost in the treated embryos, there were still intact cleithrum 
bone and part of ceratobranchial bone, both are neural crest origins (Kague et al., 2012). In 
terms of ossification, ceratobranchial5  bone is endochondrial and cleithrum is dermal (Kague et 
al., 2012). Therefore, the results show being neural crest origin or non-neural crest origin and 
being dermal or endochondrial ossifications do not play a role in these patterns of bone loss in 
RARγ agonist treated embryos. The most interesting finding in this result is all the neural crest 
derived bones anterior to the cleithrum bone were vanished apart from a very small part of 
ceratobranchial5. Therefore, it may suggest all the cranial neural crest cells before cleithrum 
bone were affected RARγ agonist treatment. This result also suggests there are possibilities that 
other neural crest derived organs may also have affected by the RARγ agonist treatment as well.  
Loss of anterior lateral line ganglion in RARγ agonist treated reinforces another clue 
for loss of neural crest. However, it seems the effect was limited to the anterior ganglion while 
the posterior and the lateral line itself seemed intact. Therefore, this suggests loss of the anterior 
lateral line ganglion in the treated embryos is neither due to the inhibitory effects on cntnap2a 
protein nor the whole neural crest contribution to the lateral line formation; it is simply due to 
the disruptive effect to the area which involves the anterior lateral line ganglion.  
Combination of loss of jaw bones and loss of anterior lateral line ganglion in RARγ 
agonist treated embryos bring rather interesting findings. Cleithrum bone is only paired vertical 
bone in zebrafish head (Eames et al., 2013) which borders with the posterior margin of otic 
vesicle. The anterior and posterior lateral line ganglions are located in the most anterior margin 
and the most posterior margin of otic vesicle respectively (Pujol-Martí et al., 2012). Therefore, 
imaginary overlapping of alizarin red staining and lateral line ganglions transgenic results in 
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5dpf treated embryos clearly suggest the affected areas is limited to the most posterior region of 
otic vesicle (Figure 4.8). 
The touch response tests showed RARγ agonist treated embryos still had the 
functioning lateral line system although they had the absence of anterior lateral line ganglion. 
However, they had weaker duration of response compared to the control embryos which may 
not be related to the functionality of the lateral line system. There are many possible causes 
which are not directly related to the lateral line system. The treated embryos had cardiac 
oedema which may cause poor circulatory effect. The oil-red-o staining from previous results 
chapter also shows lack of fat droplets within the trunk which the fat from the yolk sac is 
essential source of energy for the embryo before they can independently catch the food at 5dpf. 
Finally, the RARγ agonist treated embryos do not have the appendages involved in swimming, 
which are the pectoral, caudal fin and fewer numbers of somite.  
The results from sox9 antibody staining show loss of sox9 positive cells including 
neural crest were found in the RARγ agonist treated embryos. The pattern of antibody staining 
confirm the right staining pattern of sox9 expression according to the in-situ hybridization 
pictures (Li et al., 2002; Chiang et al., 2001). However, the results were far from conclusive 
because the experiment itself was only one repeat. Another issue of antibody staining in 
zebrafish is reliability. In fact, one of the weak points of zebrafish study is antibody staining. 
Most of the antibody staining used on zebrafish was slices rather than whole mount. In reality, 
transparency and advanced transgenic techniques favours the tide of zebrafish genetic and 
proteomic study towards the zebrafish transgenesis rather than antibody methods. And also, 
unlike the in-situ hybridization technique which has critical protocol paper (Thisse and Thisse 
2008), there is no detailed protocol paper for zebrafish antibody staining. Moreover, this 
staining result is not like tbx5a which had other ways to prove its existence and not like alpha-
actinin, which was confirmed by the somite transgenic zebrafish.   
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Nevertheless, there are still the interesting points to discuss. The results were 
suggesting loss of sox9 positive cells in RARγ agonist treated embryos and there was no sign of 
apoptosis. But, it is still difficult to pinpoint where and when they were lost. More importantly, 
there are other markers involved in neural crest formation, migration and differentiation. 
Therefore, loss of sox9 expression alone may not be the indicator of loss of neural crest. On the 
other hand, there was no sign of cell death. These all suggestions bring the possibility that the 
neural crest cells in RARγ agonist treated embryos simply switched off sox9 expression. Both 
sox9a morpholino knock-down and sox9a mutant zebfish embryos show lack of cranial skeletal 
structures with intact clithrum bone suggesting sox9a in zebrafish functions mainly for neural 
crest differentiation, not formation and migration  (Yan et al., 2002). Sox9b morpholino knock-
down zebrafish embryos also show the similar patterns to sox9a mutant zebrafish (Yan et al., 
2005). However, the fate of neural crests is not still clear in these embryos. There are numerous 
papers suggesting the role of RA in neural crest. But, it will be endless discussion to bring up 
RA effects on neural crest since there is no evidence of RARγ agonist was working through its 
receptor yet. Therefore, the best way to track down the fate of neural crest in RARγ agonist 
treated zebrafish is to use a neural crest transgenic line which has the permanent expression. A 
novel sox-10 transgenic line created using Cre-lox system shows the traceable permanent 
staining on neural crest and its derivatives (Rodrigues et al., 2012). Therefore, using the 
transgenic line for RARγ agonist treatment will provide the crucial evidence for the fate of 
neural crest in RARγ agonist treated zebrafish.   
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4.5. Summary 
This chapter explains the possible causes of three RARγ agonist treatment effects which 
were shorter antero-posterior axis, lack of pectoral fin and loss of pharyngeal arches. Antero-
posterior body axis was caused by reduced number of somite which was associated with 
changes in hoxc11a and hoxb13a expressions. The loss of pectoral fin was due to reversible 
inhibitory effects of RARγ agonist on fin outgrowth. Loss of pharyngeal arches was due to 
changes in neural crest formation which may not have gone for apoptosis.  
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Chapter 5 
An investigation of the relationship between RARγ and  
canonical Wnt signalling in zebrafish embryos  
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5.1. Introduction 
The possible mechanisms involved in the phenotypic abnormalities caused by RARγ 
agonist were investigated in the previous chapter. Changes in the expression of the regulatory 
genes or proteins that are involved in the formation of tissues affected by RARγ agonist such as 
hoxc11a, hoxb13a, myoD, sox9 and tbx5a were identified. For example, there were observed 
changes in hox genes and sox9 protein in association with disrupted formation or development 
of somites and neural crest derivatives, respectively, while tbx5a expression, which regulates 
pectoral fin development (Grandel et al., 2009) was not affected. 
Although the RARγ agonist appeared to differentially affect (or not) different signalling 
pathways that are involved in the formation of the affected tissues, these tissues all have one 
interesting common signalling pathway that regulates their development, which is the Wnt 
pathway (Martin and Kimelman 2010; Sun et al., 2008). In fact, the Wnt pathway also is known 
to have a relationship with RA signalling. For example, in zebrafish it has been shown that 
treatment with RA causes a down-regulation of Wnt3a and ntl (Orthologous to Brachyuary in 
mice) (Martin and Kimelman 2010). Therefore, it is very important to examine the potential 
involvement of Wnt signalling in the RARγ agonist effects that were previously shown.   
 Excess RA has been known for its teratogenic effects on posterior body truncation by 
disturbing ntl which is important for posterior body tissue formation (Martin and Kimelman 
2010). Other investigations in mice have shown that such truncation after RA treatment is 
accompanied by  a down-regulation of Wnt3a, apoptosis of posterior mesodermal cells, and 
diversion of these mesodermal tail bud progenitors into neurones (Shum et al., 1999). Wnt 
signalling is also involved in neural crest cell differentiation into pharyngeal arches. Wnt3a 
morpholino injected zebrafish embryos show loss of pharyngeal arches and cranial cartilages 
(Sun et al., 2008), whilst Wnt9b morphant zebrafish embryos similarly have a loss of these 
same tissues (Curtin et al., 2011). Finally, treatment with morpholinos to block expression of 
the cell surface receptor protein involved in canonical Wnt signalling pathway, frizzle b(fzb) 
147 
 
also shows a loss of pharyngeal arches and cranial cartilages (Kamel et al., 2013). Therefore, it 
is clear that Wnt signalling is required for cranial morphogenesis in zebrafish embryos and also 
that the effects of disrupting Wnt signalling are similar to the effects of treating zebrafish 
embryos with the RARγ agonist. These evidences indicate that the RARγ agonist may have 
repressed Wnt signalling which resulted in a loss of pharyngeal arches and cranial bones. Wnt 
signalling also has been implicated in pectoral fin formation and outgrowth (Grandel and Brand 
2011; Sakamoto et al., 2009; Gibert et al., 2006).  
Therefore, it is possible to hypothesise that down-regulation of Wnt signalling in RARγ 
agonist treated embryos may be the main molecular mechanism giving rise to the phenotypes 
caused by RARγ agonist treatment. To study this possibility, the effects of the RARγ agonist 
were examined using a Wnt/beta-catenin signalling reporter transgenic zebrafish line. The 
zebrafish line was generated by Shimizu et al., 2012. In detail, the line was made by the 
insertion of a plasmid which contains six Tcf/lef binding sites, a mini-p (minimal artificial 
promoter) to prevent activation of other genes, and a coding sequence for d2EGFP (destabilized 
enhanced GFP version 2), which has a rapid protein turnover rate, and is reported as a sensitive 
indicator of canonical Wnt signalling (Shimizu et al., 2012). The plasmid was delivered by the 
tol2 transposase-mediated transgenesis method (Kawakami et al., 2004). The reporter fish line 
embryos were treated with the RARγ agonist at 10nM and 4 hpf and changes in canonical Wnt 
signalling were observed using fluorescence microscopy.  
Canonical Wnt signalling includes three major steps for signal transduction and gene 
transcription which are (1) surface receptor activation (2) inhibition of beta-catenin destruction 
complex and (3) activation of a Wnt-specific nuclear receptor complex (Saito-Diaz et al., 2013). 
The Wnt cytokine binds to the cell surface receptors, frizzled and lipoprotein related protein 
(LRP5/6). Beta-catenin is continuously synthesized in the cytoplasm and destructed by APC, 
GSK-3, Axin, and CK1a complex. When the Wnt cytokine forms a complex with frizzled and 
LRP5/6, it recruits dishevelled protein which disrupts the destruction complex for beta-catenin 
resulting in increased cytoplasmic beta-catenin level. When the amount of beta-catenin level in 
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the cytoplasm reaches almost doubled of original amount, the translocation to the nucleus 
occurs and binds to Tcf/lef proteins which sit on specific DNA sequences accompanied by co-
repressor protein. Beta-catenin replaces the co-repressor protein, Groucho, and transcribes the 
Wnt-regulated genes (Figure 5.1). 
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Figure 5.1. Canonical Wnt signalling.  
The diagrammatic illustration of canonical Wnt signalling which involves the cell surface 
receptor activation, cytoplasmic protein translocation and nuclear gene transcriptions. The 
picture was adapted from (Saito-Diaz et al., 2013) and the permission to reuse this figure is 
obtained from the publisher.  
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5.2. Canonical Wnt signalling in response to RARγ agonist treatment during somitogenesis. 
 Canonical Wnt signalling in the transgenic reporter (Tcf:minip) zebrafish embryos was 
visualized from the stage when the pre-somitic mesoderm (PSM) initially formed segmented 
somites through to when all somites have formed, which is from 10hpf-24hpf ( Kimmel et al., 
1995; Stickney et al., 2000; Shimozono et al., 2013). GFP expression indicating canonical Wnt 
signalling was readily observed in the control zebrafish embryos at the 7-8 somites stage, 
including positivity in the PSM and formed somites. In contrast, although GFP expression was 
present in the RARγ agonist treated embryos at the same time point (12hpf), the levels of 
expression appeared reduced as well as showing a disorganised and diffuse pattern of positivity 
that did not match the somite patterns seen in the control fish (Figure 5.2). In contrast, at 1dpf, 
increased GFP positivity was seen in the control embryos at the presumptive tail edge while 
RARγ agonist treated embryos had loss of GFP expression in the tail area. In addition, strong 
ectopic GFP expression was also seen in the hatching glands of the RARγ agonist treated 
embryos as well as in the presumptive notochord area at the same time point. The patterns of 
canonical Wnt signalling seemed the same in the RARγ agonist and control embryos in the 
ventral and medial finfold, the otic vesicle, the pectoral fin bud, the lateral line primordium and 
at the mid-hindbrain boundary. These patterns of GFP expression were consistent, (data pooled 
from 3 independent experiments).  
Hence, canonical Wnt signalling was transiently down-regulated in the PSM of the 
developing embryo during somitogenesis stage in association with RARγ agonist treatment, 
followed by the complete loss in the tail area at 1dpf. Therefore, these evidences suggested 
canonical Wnt signalling in RARγ agonist treated zebrafish embryos was not completely down-
regulated as mentioned in Martin and Kimelman 2010 in which complete loss of Wnt mRNA 
was observed in the pre somitic mesoderm area following RA treatment. In addition, RARγ 
agonist may also have ectopic expression effects on hatching gland and notochord. 
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Figure 5.2. Treatment of zebrafish embryos with RARγ agonist (10nM) (10nM) was 
associated with no evidence of canonical Wnt signalling down-regulation.  
Representative pictures of left lateral views of treated and control Tcf:minip canonical Wnt 
signalling reporter line are shown at 7-8 somite stage and 1hpf. The activity of Tcf:minip which 
reports GFP expression during somitogenesis,  canonical Wnt signalling was partially down-
regulated in the pre-somitic mesoderm (arrowed) and developing somites in the RARγ agonist 
(10nM) (10nM)(10nM)treated embryos compared to the control embryos. At 1hpf, loss of 
canonical Wnt signalling expression was observed at the end of tail (arrowed) of RARγ agonist 
(10nM) (10nM)treated embryos compared to the control embryo. GFP expression was also 
found in the hatching gland (arrowed) as well as presumptive notochord (arrowed) of the RARγ 
agonist (10nM) (10nM)treated embryos. The scale bar represents 250µm. n=3 independent 
experiments 
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5.3. Treatment of zebrafish embryos with the RARγ agonist was associated with a temporal 
increase in canonical Wnt signalling in the posterior notochord and pectoral fin bud at 2dpf. 
At the end of the pharyngula period (48hpf) (Kimmel et al., 1995), the most obvious 
GFP expression was found in the RARγ agonist treated embryos. This was most markedly seen 
in a tubular shape which ran along the antero-posterior axis and was located at the posterior part 
of the trunk (Figures 5.3). In addition, strong GFP positivity was also seen in the pectoral fin 
bud and occasionally in the ventral fin fold. Canonical Wnt signalling was examined in a double 
transgenic embryo fish line using the Tcf;minip fish line crossed with the HuC-RFP line, where 
the HuC promoter drives RFP expression in neurons (Park et al., 2000). In these double 
transgenic report zebrafish embryos, enhanced GFP positivity was seen in the RARγ agonist 
treated embryos in a location that was ventral to the evident RFP positivity seen in the neural 
tube (Figure 5.3, lower panels). Enhanced GFP positivity was also seen in the pectoral fin bud, 
although not in the caudal fin. Hence, it appeared that treatment with the RARγ agonist was 
consistently associated with increased canonical Wnt signalling in the posterior notochord and 
the pectoral fin bud. The differential patterns of expression described for the notochord and 
pectoral fin at 2dpf were consistent in  RARγ agonist treated and control Tcf;minip zebrafish 
embryos, (data pooled from 3 independent experiments). Similarly, the patterns of expression 
seen in the double transgenic zebrafish that showed notochordal and pectoral fin bud canonical 
Wnt signalling were consistent, (data from two independent experiments).  
Canonical Wnt signalling was increased in several locations at 3dpf in control 
Tcf;minip zebrafish embryos, including the brain, pharyngeal arches, liver, pectoral fin, ventral 
fin fold and caudal fin. In contrast, the level of GFP expression in the RARγ agonist treated 
canonical Wnt signalling reporter line was decreased at 3dpf compared to the control embryos 
at all of these locations, except for the notochord and remaining fin bud (Figure 5.4). GFP 
expression in both the RARγ agonist treated and control embryos became weaker at 4dpf and 
invisible at 5dpf. These patterns of expression were consistently seen in all of the RARγ agonist 
treated embryos from 3dpf-5dpf.    
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Taken together, these data indicate that canonical Wnt signalling appeared to be 
increased prematurely in some tissues following RARγ agonist treatment, i.e.  The pectoral fin 
bud at 2dpf, as well as being aberrantly induced in the notochord from late 1dpf.  
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Figure 5.3. Treatment of zebrafish embryos with RARγ agonist (10nM )was associated with 
up-regulation of canonical Wnt signalling in the posterior end of the notochord. 
Representative fluorescent microscopic pictures show the left lateral views of RARγ agonist 
(10nM)treated and control Tcf:minip canonical Wnt signalling reporter line embryos at 2dpf. At 
2dpf, the strong expression of canonical Wnt signalling was observed in the posterior notochord 
of RARγ agonist (10nM )treated embryo (arrowed) and not in the posterior notochord of the 
control embryos. The double transgenic embryos of HuC-RFP, which has RFP expression in the 
neurons, and Tcf:minip showed the canonical Wnt signalling in the notochord of RARγ agonist 
(10nM) treated embryos at 2dpf (arrowed). The central nervous system and the neural tube in 
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both control and RARγ agonist (10nM) treated embryos expressed RFP. The scale bars 
represent 250µm. (n=2 independent experiments) 
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Figure 5.4. Treatment of zebrafish embryos with RARγ agonist (10nM) was associated with 
regression of canonical Wnt signalling from 3dpf. 
Representative fluorescent pictures show the left lateral views of RARγ agonist (10nM) treated 
and control Tcf:minip canonical Wnt signalling reporter line embryos from 3dpf to 5dpf. The 
brightest pattern of GFP expression in RARγ agonist (10nM) treated embryos was observed in 
notochord, pectoral fin, brain and ventral fin-fold (arrowed) at 2dpf but the expression became 
weaker from 3dpf. In contrast, the GFP expression of the control embryos in brain, pectoral fin, 
ventral fin-fold, pharyngeal arches and liver became stronger at 3dpf (arrowed) while these 
expressions in the RARγ agonist (10nM) treated embryos became weaker at 3dpf. However, 
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5dpf 
3dpf 
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Control 
RARγ agonist 
Control 
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both RARγ agonist (10nM) treated and control embryos showed very weak expression from 
4dpf to 5dpf. The scale bars represent 250µm. (n=3 independent experiments) 
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5.4. The apc
-/-
 mutant zebrafish embryos exhibit a similar phenotype to RARγ agonist (10nM) 
treated wild type zebrafish embryos. 
 The previous findings suggested that the phenotypes of RARγ agonist (10nM) treated 
zebrafish embryos were very likely to be associated with premature up-regulation of canonical 
Wnt signalling. To compare the phenotypic similarities between RARγ agonist (10nM) treated 
embryos and canonical Wnt signalling up-regulated embryos, the characteristics of apc
-/-
 mutant 
zebrafish were analysed. The apc
-/-
 mutant zebrafish (Hurlstone et al., 2013) carries the 
mutation in apc (adenomatous polyposis coli) resulting in defective beta-catenin degradation 
mechanism and permanent activation of canonical Wnt signalling.  
The heterozygous zebrafish line that carries a mutation for the apc gene has a normal 
phenotype. After crossing parental heterozygous zebrafish carrying this apc mutation, there 
were a number of similarities between the phenotype seen and the resultant apc
-/-
 mutant 
embryos, in which canonical Wnt signalling is constitutively on (Hurlstone et al., 2013), and the 
RARγ agonist (10nM) treated zebrafish embryos. In particular, the apc-/- mutant zebrafish 
embryos had a malformed head and showed lack of pectoral fin formation at 3dpf (Figure 5.4). 
The apc
-/-
  mutant embryos also had a shorter body axis, a malformed caudal fin, cardiac 
oedema and smaller eyes, as seen in lateral views (Figure 5.5; bottom panel), compared with the 
apc
+/-
 siblings. Interestingly, although the caudal fin formation appeared to be abnormal in apc
-/-
 
embryos, the caudal fin formation was not completely diminished (arrowed in Figure 5.5) as in 
RARγ agonist (10nM) treated embryos at 3dpf.  
Taken together, the similarity between the RARγ agonist (10nM) treated embryos and 
the apc
-/-
 mutant embryos, as well as the increased and premature canonical Wnt signalling seen 
in some locations after RARγ agonist (10nM) treatment, suggests that RARγ may have 
increased Wnt signalling to result in the phenotypes seen. However, the truncated caudal fin 
formation in RARγ agonist (10nM) treated embryos may not be related to the premature up-
regulation of canonical Wnt signalling.  
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Figure 5.5. Characterization of apc homozygous mutant zebrafish embryo at 3dpf 
Representative pictures show the phenotypic differences between apc
+/-
 and apc
-/-
 embryos at 
3dpf. The dorsal views show the changes in head morphology and the lack of pectoral fins in 
apc
-/-
 embryos. The left lateral views show shorter body axis, smaller eyes, cardiac oedema and 
abnormal caudal fin formation. The scale bars represent 250µm. (n=3 independent experiments) 
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5.5. Treatment with the RARγ agonist (10nM) failed to rescue fin fold formation in 
krt4p/dkk2-rfp transgenic zebrafish.  
The previous data suggested RARγ agonist (10nM) treatment was linked to the 
premature up-regulation of canonical Wnt signalling. To investigate whether the RARγ agonist 
was working by affecting intracellular or extracellular elements of the Wnt signalling pathway, 
a transgenic zebrafish line was used in which dickkopf related protein (Dkk) was expressed in 
the skin and fin folds under the control of the krt4p promoter (Wada et al., 2013). Dkk works as 
a negative regulator of canonical Wnt signalling by degrading the LRP5/6 co-receptor for Wnt 
(Saito-Diaz et al., 2013). In this Gal4: UAS transgenic system line of krt4p/dkk2-rfp embryos, 
the Gal4 protein was driven by keratin 4 promoter which is predominately expressed in the 
finfold and skin. Therefore, dkk-rfp  is expressed in the skin and fin folds, which can be seen 
through the presence of rfp.  However, in these embryos fin formation is inhibited because 
canonical Wnt signalling is required and this is inhibited by Dkk. The hypothesis, therefore, 
was that if the RARγ agonist increased canonical Wnt signalling through altering intracellular 
elements of this signalling pathway, rather than affecting extracellular elements (e.g. by directly 
increased Wnt expression), then treatment of  
Fin fold formation is normally observed in wild type embryo at 2dpf. However, fin fold 
formation was not seen in krt4p/dkk2-rfp embryos at this same time point (Figure 5.6). The 
phenotype of the RARγ agonist (10nM) treated krt4p/dkk2-rfp embryos was similar to that of 
wild type RARγ agonist (10nM) treated embryos, in that there was truncation of the antero-
posterior body axis. In addition, although RFP expression was seen in the skin of these 
embryos, indicating Dkk expression, there was no fin fold formation in the RARγ agonist 
(10nM) treated embryos at 2dpf (Figure 5.6). This indicated that RARγ agonist (10nM) was not 
increasing Wnt signalling through changing elements of the pathways that were downstream of 
Dkk/LRP but from extracellularly instead. 
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Figure 5.6. Treatment of zebrafish embryos with RARγ agonist (10nM) was associated with 
failure to rescue the fin fold formation in krt4p/dkk2-rfp transgenic embryo 
Representative pictures show the posterior left lateral views of wild type, krt4p/dkk2 embryos 
and RARγ agonist (10nM) treated krt4p/dkk2 embryos at 2dpf. Normal fin-fold formation was 
found in wild type zebrafish embryos at 2dpf. However, fin-fold formation was inhibited in 
Wild type 
Krt4p/dkk2-rfp 
Wild type treated 
Krt4p/dkk2-rfp 
treated 
Wild type treated 
Krt4p/dkk2-rfp 
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krt4p/dkk2 embryos at 2dpf. RARγ agonist (10nM) treated krt4p/dkk2 embryos also did not 
have the fin-fold formation. The scale bars represent 250µm. (n=3 independent experiments) 
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5.6. RARγ and canonical Wnt signalling following caudal fin transection 
 The RARγ agonist has been shown to affect the development of tissues derived from 
stem/progenitors cell pools where RARγ is expressed, i.e. the neural crest, lateral plate 
mesoderm and presomitic mesoderm (Hale et al., 2006; Waxman and Yelon 2007; Martin and 
Kimelman 2008). This was associated with altered canonical Wnt signalling. However, the 
treatment with RARγ agonist was at 4hpf stage in the development of the zebrafish embryos 
(4hpf throughout), which means that phenotypic effects seen may have been due to downstream 
events rather than direct effects on the RARγ expressing stem/progenitor cell pools. In addition, 
a recent study has reported that RA may influence gene expression without necessarily 
engaging with RAR by triggering intracellular kinase signalling pathways (Gudas, 2013).  
 To try to address the possibility of the RARγ agonist having non-RARγ specific activity 
on cells that were not from stem/progenitor pools, experiments were performed to examine the 
effects of the agonist on caudal fin regeneration following transection. This was done in wild 
type zebrafish embryos and in the Tcf;minip reporter zebrafish line because it is known that 
RARγ is up-regulated in the blastemal cells specifically during regeneration (White et al., 
1994). In addition, it is also known that Wnt expression is up-regulated during the regenerative 
process (Tal et al., 2010). Although the involvement of canonical Wnt signalling in larval fin 
regeneration has not been reported, caudal fin regeneration was examined during embryonic 
development because this is rapid, i.e., it occurs within 2-3 days of transection (Kawakami, 
2004; Yoshinari and Kawakami, 2011).  
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5.7. Treatment of zebrafish embryos with RARγ agonist was associated with a reversible 
inhibition of caudal fin regeneration and changes in canonical Wnt signalling. 
The zebrafish larval caudal fin was transected at 2dpf and treated with 10nM RARγ 
agonist versus carrier alone (control). The larval caudal fin of the control embryos regenerated 
following transection to grow beyond the original line of transection. In contrast, the transected 
fins of RARγ agonist treated embryos did not regenerate such that at 5dpf they had not re-
grown beyond the line of transection (Figure 5.7 top panels). Moreover, treatment with the 
RARγ agonist was also associated with a different distribution of melanocytes in the tail area. In 
the control embryos, melanocytes were absent from the dorsal area beneath the notochord, 
which is from where mesodermal progenitors arise during caudal fin patterning (Hadzhiev et 
al., 2007) whereas melanocytes were seen to completely surround the notochord in the RARγ 
agonist treated embryos such that no gap was observed. This difference in the regeneration of 
the caudal fin and differential pattern of melanocyte distribution was consistent. 
The inhibitory effects of the RARγ agonist on caudal fin regeneration were reversible. 
When the caudal fins were amputated and treated with the RARγ agonist (10nM) at 2dpf, but 
then subsequently were either co-treated with RARγ antagonist (10nM) at 3dpf or the media 
containing the RARγ agonist was removed and replaced with control media (wash out), there 
was increased fin regeneration beyond the site of transection (Figure 5.7 bottom panels). These 
observations were also completely consistent, with fin regeneration re-initiated in RARγ 
antagonist treated embryos and  wash out embryos. 
The caudal fins of Tcf;minip zebrafish embryos were transected at 3dpf rather than 
2dpf (as was done in the wild type embryos) because GFP positivity is not seen at this stage of 
development (see Figure 5.3). However, caudal fin regeneration was also seen in these embryos 
at 4-5dpf, i.e. within 1 to 2 days post transection. In addition, increased GFP positivity was seen 
in the regenerating fins. This indicated that canonical Wnt signalling was associated with caudal 
fin regeneration in larvae. In contrast, there was no evidence of increased GFP positivity in the 
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transected caudal tips of the embryos when they were treated with the RARγ agonist (Figure 
5.8). Hence, the inhibition of caudal fin regeneration may be linked to a lack of canonical Wnt 
signalling. However, increased GFP positivity was seen in the RARγ agonist treated embryos in 
the notochord. This differential pattern of GFP expression was consistent, being seen in all 
RARγ agonist treated and all control embryos. Therefore, these evidences suggest the effects of 
RARγ agonist on canonical Wnt signalling might be different depending on the developmental 
or regeneration process. 
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Figure 5.7. Treatment of zebrafish embryos with the RARγ agonist (10nM) was associated 
with reversible block in larval caudal fin regeneration. 
Representative phase contrast microscopy pictures show the caudal fin regeneration in AB wild 
type zebrafish embryo at 5dpf after the caudal fin transection at 2dpf. The caudal fin was 
regenerated in the control embryo following the trasncetion at 2dpf (top left). However, the 
caudal fin regeneration was blocked in RARγ agonist (10nM) treated embryo at 5dpf (top 
right). Regeneration was restored in RARγ agonist (10nM) treated embryos at 5dpf after either 
washing out the RARγ agonist (10nM) at 24 hour  post transection (bottom right) or adding an 
equal dose (10nM) of the RARγ antagonist at 24 hour post transection (bottom left). The scale 
bars represent 250μm. (n=3 independent experiments) 
Control RARγ agonist: 0hpa 
+ RARγ antagonist: 24hpa + wash out: 24hpa 
RARγ  agonist: 0hpa RARγ agonist: 0hpa 
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Figure 5.8. Treatment of zebrafish embryos with RARγ agonist (10nM) was associated with 
loss of canonical Wnt signalling in regenerating fin but up-regulation in the notochord. 
Representative fluorescence microscopy pictures of canonical Wnt signalling in the transgenic 
zebrafish Tcf:mini-P reporter line. A low level of GFP expression to indicate canonical Wnt 
signalling was seen in the caudal tail of non transected zebrafish embryos at 4dpf (top). In 
contrast, there was a marked up-regulation in GFP expression demonstrating increased 
canonical Wnt signalling in the regenerating caudal fins of control embryos at the same time 
point, i.e. at 4dpf and 1 day after transection (white arrows) (bottom). No GFP-evident 
canonical Wnt signalling was seen in the transected fins of the RARγ agonist (10nM) treated 
embryos at 4dfp and 1 day after transection. These embryos did not regenerate transected 
caudal fins. However, increased canonical Wnt signalling was seen in the notochord (white 
arrow) (middle).  Scale bars represent 250µm. (n=3 independent experiments) 
  
Un-amputated caudal fin 
at 4dpf 
RARγ agonist: 0hpa at 
4dpf 
Control at 4dpf 
168 
 
5.8. Discussion 
The results of RARγ agonist treatment to the canonical Wnt signalling reporter 
transgenic zebrafish line generally showed that the premature up-regulation of GFP expression 
in the notochord was associated with RARγ agonist treatment (Figure 5.2, Figure 5.3 and Figure 
5.4). The up-regulation of GFP expression in the notochord of RARγ agonist treated embryos 
suggests the effects might be directly activated by RARγ agonist. The patterns of GFP 
expression also showed the up-regulation occurred from 1dpf to 2dpf followed by regression 
after 3dpf. Interestingly, the regression pattern in the notochord of the RARγ agonist treated 
embryos happened from anterior to posterior which may be the effects of agonist diffusion. The 
most posterior part of the RARγ agonist treated embryos might still have had more contact with 
the diffused agonists because of the wedged shape embryo in which the anterior part of the 
embryo was thicker than the posterior part of the embryo suggesting that agonist diffusion was 
more accessible to the notochord in the posterior part of the embryo. Another interesting finding 
was lack of GFP expression in the pharyngeal arches of RARγ agonist treated embryos from 
2dpf to 3dpf (Figure 5.4). This finding agreed with the sox9 antibody staining results from 
chapter 4 which showed lack of sox9 positive neural crest staining in the treated embryos at 
60hpf. In general, all the canonical Wnt signalling expression areas in the RARγ agonist treated 
embryos were weaker than those of control embryos apart from the ectopic expression in 
notochord. However, the expression in both RARγ agonist treated and control embryos became 
weaker in 4dpf and the weakest in 5dpf.  
These findings suggested the ectopic expression in the notochord may be the direct 
effects of RARγ agonist on canonical Wnt signalling. Canonical Wnt signalling may play the 
important roles in the zebrafish development before 4dpf reaching the highest level of 
expression at 3dpf. However, the canonical Wnt signalling in the RARγ agonist treated embryos 
showed the premature peak at 2dpf and early regression at 3dpf. Therefore, canonical Wnt up-
regulation caused by RARγ agonist could possibly be the main driving force which caused the 
phenotypes reported in Chapter 3. 
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Previous results showed the canonical Wnt signalling started from the most posterior 
part of the tail in the RARγ agonist treated embryos suggesting it might be the direct effects of 
RARγ agonist on canonical Wnt signalling. Moreover, the pattern of canonical Wnt signalling 
was the strongest in the most posterior region and the weakeest in the anterior region. The 
thickness of the zebrafish body is the thinnest in the most posterior region suggesting the 
penetration of RARγ agonist may play a role in the intensity of Wnt signalling and the level of 
expression may be concentration dependent.  
Characterization of apc
-/- 
mutant zebrafish embryos   showed the similar phenotypes 
between RARγ agonist treated embryos and apc-/- mutant embryos at 3dpf. The morpholino 
knock down of the apc gene in zebrafish embryos also showed the same phenotypes as apc
-/- 
 
mutant embryos (Nadauld et al. 2004). Therefore, the results of apc
-/- 
mutant zebrafish embryos 
were consistent with RARγ agnist treatment of zebrafish causing the abnormal phenotypes by 
up-regulating of canonical Wnt signalling.  
In the next experiment, the possible mechanism in which RARγ agonist interacted with 
the canonical Wnt signalling was further investigated. Since the retinoid is a lipophilic molecule 
which can interact with a cytoplasmic receptor (Rhinn and Dollé 2012), the experiment was set 
up to investigate whether RARγ agonist activated intracellular canonical Wnt signalling or 
extracellular pathways. The results showed RARγ agonist failed to rescue the finfold formation 
when dkk was activated in the finfold area to interrupt the canonical Wnt signalling at the cell 
membrane level. Therefore, it suggested the RARγ agonist might be activating the canonical 
Wnt signalling extracellularly.  
The results from this Chapter so far agree with the finding of cross talk between RA 
signalling and canonical Wnt signalling in mouse chrodrocyte cell culture  (Yasuhara et al., 
2010). These in vitro results show canonical Wnt signalling can be activated by RA treatment 
without Wnt cytokine in mouse chondrocytes. This activity is inhibited by co-treatment of dkk 
protein suggesting RA activation needs the intact surface receptor proteins. Interestingly, the 
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canonical Wnt signalling in these chondrocytes was inhibited by over-expression of RAR 
gamma receptor, not alpha and beta, suggesting that the release of the repressor activity of RAR 
gamma receptor on canonical Wnt signalling may be what is important. Their experiments also 
reported that ligand free RAR gamma receptor induces the dissociation of beta catenin from Tcf 
protein by binding to the beta catenin itself which may explain why the RAR gamma 
overexpression inhibited canonical Wnt signalling. Therefore, these in vitro findings support the 
results of canonincal Wnt signalling in RARγ agonist treated embryos.  
Although the results suggested RARγ agonist needed the LRP membrane receptors to 
activate the canonical Wnt signalling, it is still not clear how it actually worked. The results 
from mouse chondrocyte (Yasuhara et al., 2010) suggested that the repressor role of RAR 
gamma was inhibition of beta-catenin association to Tcf. Therefore, in our experiments, treating 
with RARγ agonist may have switched off the repressor role of the RARγ receptor favouring 
more beta-catenin binding to Tcf. If it was true, the RARγ agonist should have been able to 
activate the Wnt signalling in dkk expressing transgenic line. Therefore, it suggests activation 
of canonical Wnt signalling by RARγ agonist was not solely dependent on the repressor activity 
of RARγ; it also needed the role of membrane receptors.  Hence, the cross talk between Wnt 
signalling and RA signalling may involve more than one mechanism. Another interesting 
question is why RARγ agonist needed the intact membrane LRP5/6 co-receptor although the 
RARγ agonist/retinoid itself is intracellular ligand (Rhinn and Dollé 2012). Therefore, it is 
interesting to know whether RARγ agonist itself can bind to the receptor or increase Wnt 
production. The level of Wnt cytokine expression in RARγ agonist treated embryos needs to be 
investigated. Recent studies show RA can activate non-genomic signalling pathways by 
interacting directly with  kinases and cell-surface receptor (Al Tanoury et al., 2013) although 
there is no report of interaction between retinoid and frizzled/LRP5/6 receptors.  
In summary, the results showed the canonical Wnt signalling involvement in RARγ 
agonist treated embryos suggesting the up-regulation of canonical Wnt signalling played an 
important role for the phenotypes caused by RARγ agonist treatment. The results also suggested 
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the importance of RARγ agonist as a repressor to inhibit the beta-catenin and the mysterious 
role of RARγ agonist on the cell surface receptors for Wnt is yet to be investigated. 
The caudal fin regeneration results showed interesting similarities between RARγ 
agonist on fin regeneration and pectoral fin formation. The growth of both tissues was 
reversibly inhibited by RARγ agonist. Therefore, RARγ agonist may be anti-
proliferative/regenerative on these tissue outgrowths. However, it is still not yet clear how 
RARγ agonist affected the blastema. Although zebrafish RAR gamma is expressed at 
regenerating adult caudal fin (White et al. 1994) and at the tailbud during somitogenesis 
(Waxman & Yelon 2007; Hale et al. 2006), it is still not known whether  RARγ is expressed 
during larval caudal fin regeneration. Nevertheless, these results suggested there was a 
possibility that RARγ may have interrupted the pluripotent cells in the regenerating caudal fin 
preventing the outgrowth required for regeneration.  
The results of RARγ agonist on canonical Wnt signalling of regenerating larval caudal 
fin showed the paradoxical effects of RARγ agonist on canonical Wnt signalling during 
embryonic development. However, the opposite effects, the up-regulation found in the adjacent 
tissue, the notochord, versus the down-regulation found in the regeneration caudal fin 
suggesting the interactions between RARγ agonist and canonical Wnt signalling may not be the 
same during embryonic development and the regeneration process.  
 
 
 
 
 
 
172 
 
Chapter 6 
Discussion 
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6.1. RARγ agonist and stem/progenitor cells 
This study was performed to examine the potential role of RARγ in the regulation of 
embryonic development and tissue regeneration using wild type and reporter transgenic 
zebrafish as model systems. It was demonstrated that treatment of embryonic zebrafish with a 
RARγ specific agonist had profound developmental consequences, including decreased 
anterior-posterior growth, inhibition of cranial bone and neural tissue formation, and loss of 
growth of the pectoral and caudal fins, as well as abrogation of caudal fin regeneration 
following fin transection. It was also noted that RARγ agonist treated fish exhibited cardiac 
oedema. These findings strongly suggest that RARγ activity must be tightly regulated during 
normal embryonic development and tissue regeneration.  
The tissues that were affected by treatment with the RARγ agonist derived from those 
stem/progenitor cell populations in which zebrafish rarg expression is restricted during early 
embryonic development, i.e., in the cranial neural crest, in the lateral plate mesoderm, and in 
the pre-somitic mesoderm of the tail bud (Hale et al., 2006; Waxman and Yelon, 2007). In 
addition, the tissues affected by the RARγ agonist also mirror those that are similarly affected 
by morpholino gene knock down of rarga and rargb, namely the pharyngeal arches, pectoral 
and caudal fins (Linville et al., 2009). Furthermore, this phenotype is similar to the effects of 
RA treatment on embryonic development (Shum et al., 1999). Taken together, this suggests that 
the agonist used in the current study was specific for RARγ in zebrafish, as has been 
conclusively demonstrated in mammalian reporter cell lines (Hughes et al., 2006). 
The mechanisms involved in the developmental changes observed have been examined 
using a combination of transgenic reporter fish lines, in situ hybridisation and immunohistology 
for several important genes and appropriate stem/progenitor cell markers. The shorter body axis 
formation seen in RARγ agonist treated embryos was associated with decreased somite 
formation, as revealed in hspGFF55B transgenic embryos, in situ hybridisation of myoD 
expression and α actinin immunolocalisation. Analysis of the hoxc11a and hoxb13a transgenic 
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reporter fish lines demonstrated that the shorter body axis was largely the result of loss of the 
most posterior region of the embryos. Precise expression of the hox gene family is necessary for 
normal anterior-posterior axis formation in vertebrates (Wellik 2007). Hoxc11 is 
developmentally expressed in the posterior region of the mouse embryo (Hostikka and 
Capecchi, 1998) and homozygous knock-out of the hoxc-cluster results in loss of caudal 
vertebrae (Suemori and Noguchi 2000; Wellik et al., 2007). In mice, hoxb13 expression occurs 
in the tail bud area around E9 (Zeltser et al., 1996). Hoxb13 expression is also found in the 
developing tail of axolotl and re-expressed in the regenerating tail after transection (Carlson et 
al., 2001). These expression patterns suggest that hoxb13 plays an important role in the 
development and growth or regrowth of the tail. Conversely, a heterozygous knock out of 
hoxb13 in mice was shown to cause overgrowth of the tail (Economides et al., 2003). The 
observation of a complete loss of hoxb13a expression in RARγ agonist treated zebrafish 
supports the hypothesis that this gene is essential for the formation of the posterior regions of 
developing embryos and may be regulated by RARγ. Extra-somitic expression of hoxb13a was 
also seen in the anal fin area of the control embryos, which was completely lost in the RARγ 
agonist treated embryos. Other researchers have similarly reported Hoxb13 expression in the 
hindgut and urogenital area of mice (Zeltser et al., 1996). Hence, the observation further 
suggests that treatment with the RARγ agonist targeted hoxb13a expression. Interestingly, 
hoxb13a expression was rescued by the removal of RARγ agonist or co-treatment of RARγ 
antagonist suggesting the loss of hoxb13a expression was transient. Moreover, it was also 
shown that re-expression of hoxb13a was also associated with regeneration of the caudal fin 
following transection. However, it remains a possibility that hoxb13a expression may simply be 
absent from the RARγ agonist treated embryos, because the tissues in which hoxb13a is 
normally expressed during development, including the anal area were not formed. A loss of hox 
gene expression in response to treatment with a RAR agonist is certainly paradoxical as RARE 
is located within the regulatory region of hox gene clusters (Zhang et al., 2000), which are 
normally up-regulated in response to RA (Pöpperl and Featherstone 1993; Huang et al., 2002; 
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Oliveira et al., 2013). Such a paradox may be resolved if RARγ does not require RA or indeed 
does not function through RARE to regulate target gene expression. 
The marked morphological changes seen in the head of the RARγ agonist treated 
embryos were associated with loss of cranial bones and the anterior lateral line ganglia as 
revealed by alizarin red staining and the HGn39D transgenic fish line, respectively. These 
tissues form from the neural crest, as well as the placode for the lateral line (Collazo et al., 
1994). This suggests that RARγ agonist treatment may have targeted neural crest 
stem/progenitor cells, which are known to express RARγ (Hale et al., 2006; Waxman and 
Yelon, 2007). The fact that there were significantly fewer sox9 immunopositive cells in the 
cranial region of the RARγ agonist treated embryos might be considered to support this 
hypothesis. However, this difference was only seen in later time points, i.e. at 60hpf but not at 
25hpf, even though RARγ is expressed at the earlier time point. Furthermore, even at 60hpf, 
sox9 immunopositive cells were still observed in the cranium. Therefore, it is also possible that 
fewer sox9 immunopositive cells were prevalent within the anterior cranial regions of the RARγ 
agonist treated embryos simply because the anterior tissues did not form. Further research is 
required to examine whether the loss of sox9 neural crest stem/progenitor cells following 
treatment with the RARγ agonist is causal to the loss of anterior cranial tissues observed. 
However, it is noteworthy that sox9a or sox9b morpholino knock-down and sox9a mutant 
zebrafish embryos were shown to lack cranial skeletal structures (Yan et al., 2002; Yan et al., 
2005). These developmental defects were associated with sox9 aberrant neural crest 
stem/progenitor cell differentiation, rather than any changes in neural crest formation or cell 
migration. Similarly, it was concluded that treatment with the RARγ agonist did not markedly 
affect the formation of neural crest stem/progenitor cells, as depicted by sox9 immunopositive 
cells at 25hpf, but may well have influenced their survival, proliferation, migration or 
differentiation thereafter, to adversely affect the development of cranial tissues. 
Although almost all of the neural crest derived cranial bones were absent or greatly 
decreased in the RARγ agonist treated embryos, there were still fully intact cleithrum bones, 
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which also are of neural crest origin (Kague et al., 2012). There is no clear explanation for this 
difference. However, it is interesting that cleithrum bones undergo a process of dermal 
ossification, unlike other affected cranial bones that undergo endochondral ossification (Kague 
et al., 2012; Eames et al., 2013).  
An additional major phenotype seen following treatment with the RARγ agonist was 
the loss of pectoral fin outgrowth, despite formation of the fin bud. Other studies have reported 
that the interaction of RA signalling with expression of the tbx5a transcription factor is essential 
for pectoral fin formation. Increased raldh1a2 expression and its localized synthesis of RA in 
the region of somites 2-6, where tbx5a expression is induced in response to RA, is required for 
formation of the pectoral fin (Gibert et al., 2006). Both the nls (neckless) mutant zebrafish, 
which carries a mutation in raldh1a2 (Grandel et al., 2002), and embryonic zebrafish that have 
been treated with the RA synthesis inhibitor, diethylaminobenzyldehyde (DEAB), do not 
express tbx5a and do not form pectoral fins (Grandel and Brand 2011). Moreover, loss of 
function tbx5a mutations block pectoral fin formation, as well as causing heart defects (Garrity 
et al., 2002). Zebrafish tbx5a expression can be seen from 14hpf in the lateral late mesoderm in 
the common stem/progenitor cell population for the development of the heart and pectoral fins, 
which separate from 24-27hpf (Albalat et al., 2010). Because the pectoral fins did not form in 
RARγ agonist treated embryos in this study, tbx5 was considered a potential target gene for 
RARγ agonism. However, it was also found that there were no marked differences in the 
presence of tbx5a-immunopositive stem/progenitor cells in the RARγ agonist treated or control 
embryos, suggesting that tbx5a expression was unaffected. Furthermore, RARγ agonist wash 
out experiments or co-treatment with a RARγ specific antagonist (as well as the agonist) 
completely abrogated the block of pectoral fin formation, demonstrating that tbx5a was 
functional. Finally, treatment with the RARγ agonist at 27hpf, which was confirmed as when 
tbx5a was present in the lateral plate mesoderm, was also found to completely block pectoral fin 
outgrowth. Therefore, it can be concluded that the effect of RARγ agonist treatment on pectoral 
fin outgrowth was independent of tbx5a. Potential targets that lie downstream of tbx5a activity 
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include fgf family genes, i.e.,  fgf8, fgf10 and fgf24 (Ng et al., 2002; Fischer 2003), as well as 
sall4 (Harvey and Logan, 2006), blimp-1 (Lee and Roy, 2006), prdm1 (Mercader et al., 2006), 
beta-CaMK-II (Rothschild et al., 2009) and ndrg4 (Qu et al., 2008). In addition, hox gene 
expression was also associated with pectoral fin formation, including hoxa (Géraudie and 
Borday Birraux 2003), hoxb (Waxman et al., 2008) and hoxd  (Sakamoto et al., 2009; Neumann 
et al., 1999). Further study will elucidate if RARγ agonist treatment alters the expression of 
each of these genes, but given our finding that hoxb13a was completely inhibited by such 
treatment, this family is a clear target. 
Lastly, it was tested whether the RARγ agonist affected tissue regeneration as well as 
development using transection of the caudal fin as a model. This was because RARγ is 
expressed in the distal edges of blastemal cells at least during adult zebrafish caudal fin 
regeneration (White et al., 1994). Similar to the findings with pectoral fin outgrowth, it was 
found that RARγ agonist treatment was associated with a complete, but reversible block on 
caudal fin regeneration. Canonical Wnt signalling is known to play a major role in caudal fin 
regeneration (Tal et al., 2010). Therefore, we investigated whether this pathway was affected by 
treatment with the RARγ agonist using the transgenic reporter line, Tcf:mini-P (Shimizu et al., 
2012). As it was hypothesised, the block in caudal fin regeneration following RARγ agonist 
treatment was associated with an observed reduction in Wnt signalling, suggesting that the Wnt 
pathway is a target for RARγ. However, similarly to our observations of sox9 immunopositive 
cells in the cranial neural crest, there is also the possibility that Wnt signalling was not seen 
following transection of the caudal fin and treatment with the RARγ agonist because the 
regenerating tissues did not form. Therefore, further study is required to determine whether the 
evident loss of Wnt signalling following RARγ agonist treatment is causal to the lack of a 
regenerative response. 
The results show that the tissues which express rarg in zebrafish were affected by the 
RARγ agonist. These rarg expressing tissues are the pectoral fin, the neural crest and the tail-
bud (Hale et al., 2006; Waxman and Yelon 2007). Interestingly in zebrafish, the time-points of 
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rarga and rargb expressions in these tissues are coincided with the time-points in which the 
stem/progenitor cells are formed in the respective tissues. For example, localized high level 
expression of rargb is reported in the tail-bud area at 10hpf (Waxman and Yelon 2007). In 
zebrafish development, 10hpf stage is the time-point that somitogenesis starts (Kimmel et al., 
1995). During somitogenesis, zebrafish tail-bud serves as a stem/progenitor cells zone known as 
pre-somitic mesoderm which constantly produces the somites (Rhinn and Dollé 2012; Stickney 
et al., 2000). Both rarga and rargb expression are found in the tail-bud area until the 15-somite 
stage but rargb expression persists until 24hpf (Waxman and Yelon 2007), which is the time 
point of somitogenesis completion (Stickney et al., 2000). At 24hpf, both rarga and rargb 
expression are found in the lateral plate mesodermal regions of somites 2 to 6 (Waxman and 
Yelon 2007). Lateral plate mesoderm at 24hpf in these areas is where the heart and pectoral 
progenitor cells are accumulated (Gibert et al., 2006; Grandel et al., 2002). Moreover, rargb 
expression is also found in the areas that form the pharyngeal arches from cranial neural crest at 
24hpf (Waxman and Yelon 2007), and again, neural crest cells are multi-potent stem/progenitor 
cells (Rodrigues et al., 2012; Dutton et al., 2001). Therefore, the expression of rarga and rargb 
appears to be related to the presence of stem/progenitor cells.  
Another interesting fact is these rarga and rargb expressing tissues are not located 
within the intrinsic range of the presence of RA. A  transgenic zebrafish line which provides 
evidence of the intrinsic distribution of RA showed a complete lack of RA in the tail-bud area 
during somitogenesis (Shimozono et al., 2013). In fact, the RA synthesizing enzyme (raldh2) is 
not expressed in the tail-bud area during the somitogenesis stage (Grandel et al., 2002). 
Moreover, the presomitic mesoderm during somitogenesis is protected from RA by expression 
cyp26a1, the RA degrading enzyme (Dobbs-McAuliffe et al., 2004). Similar patterns of raldh2 
and cyp26a1 expression are found in pectoral fin formation. Raldh2 expression in the 
intermediate mesoderm of somite numbers 2 to 6 is found at the 12-13 somite stages, to induce 
the tbx5a for cardiac and pectoral fin progenitor cells (Grandel and Brand 2011). However, 
when the pectoral fin bud is formed and starts to grow from 27pf (Albalat et al., 2010), the fin 
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growth from lateral plate mesoderm in the proximal to distal direction results in the growing 
part of pectoral fin receiving the lowest level of RA (Grandel and Brand 2011). In fact, it has 
been suggested that the growing pectoral fin expresses cyp26a1 from 24hpf to prevent the 
effects of RA (Dobbs-McAuliffe et al., 2004). At the same time, rarga expression is found in 
the lateral plate mesoderm from 24hpf to the formation of the pectoral fin at 48hpf (Hale et al., 
2006). The expression patterns of rarga and rargb in the cranial neural crest are also similar to 
the previous tissues. The strong expression pattern of rarga is observed in the pharyngeal neural 
crest at 48hpf (Hale et al., 2006). Although raldh2 expression is found in the zebrafish head 
area from 30hpf to 48hpf, it is not expressed in the pharyngeal arches where cyp26a1 is heavily 
expressed (Dobbs-McAuliffe et al., 2004). Therefore, the data above suggests the rarg in 
zebrafish may need protection from the influence of RA in regulating gene expression by co-
expressing cyp26a.  
 The possible answer to this paradox is that the RA receptors can work as co-repressors 
of gene expression activity and this has been shown in mice (Koide et al., 2001; Williams et al., 
2009). However, it has been reported that zebrafish rara may not have co-repressor activity 
(Waxman and Yelon 2011). Therefore, the findings of this study are clearly contradicting the 
previous finding regarding by Waxman and Yelon (2011), as they also suggest the necessity of 
rarg as repressor. There are two ways to prove the repressor activity of RARγ is important. 
First, if a tissue or cell needs a receptor as a repressor, this tissue or cell function will be 
disrupted when an agonist switches its receptor to become that of a transcriptional activator. 
Here, the results showed the tissues which expressed rarg were disrupted by agonism 
suggesting it has repressor activity. Secondly, if the receptor is needed as a transcriptional 
repressor, the mutant or morphant zebrafish of this gene will have phenotypes associated with 
the tissues or cells that express receptor. There is no current analysis on rarg zebrafish mutant 
lines, but rarg morpholinos knock down zebrafish morphant show effects on pectoral fin 
outgrowth, pharyngeal arches and the tail (Linville et al., 2009). The combination of results 
presented in this thesis and the morpholinos results suggests the rarg may have a role in 
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repressing gene expression. Another interesting question is the main repressive function of rarg. 
Although its exact function is not still clear, it is heavily involved in stem cell maintenance.  
RARγ (-/-) murine embryonic stem cells lose gene expression in a number of genes, including 
cyp26a1, which prevents RA signalling (Kashyap et al., 2013). Furthermore, the rate of RARγ 
overexpression in murine somatic cells used for induced pluripotency experiments was directly 
related to the rate and efficiency of reprogramming the cells into pluripotent stem cells (Wang 
et al., 2011). Here, the results of this study showed that the stem cells niches were affected by 
RARγ agonism, such as pre-somitic mesoderm (Rhinn and Dollé 2012), neural crest (Rodrigues 
et al., 2012) and the forming pectoral fin, which also has shown its involvement in regenerative 
capacity (Yano et al., 2012). The caudal fin regeneration results also showed repressor activity 
on blastemal cells, because rarg is one of the genes network involved in the regenerating 
blastema of caudal fin (White et al., 1994), while there is raldh2 expression in the proximal 
area of the caudal fin rather than the blastema itself.  
The last issue to solve is to determine if the effects caused by RARγ agonist treatment 
were purely due to disruptive effects on repressive activity alone or combination of repressive 
activity disruption and transcriptional activation. In other words, can the RARγ agonist activate 
the transcription by binding RAR/RXR complex? The conventional RA signalling pathway 
involves the formation of the RAR/RXR complex and transcriptional activation via RARE 
(Rhinn and Dollé 2012). Using the transgenic zebrafish line (RARE:YFP), which drives the 
reporter gene using RARE (Perz-Edwards et al., 2001), has revealed a variety of areas where 
intrinsic RA signalling occurs throughout the zebrafish development. Interestingly, all the 
tissues in which the presence of RA signalling was detected, from the 18 somite stages through 
to 3dpf, do not include the tissues in which rarg is expressed, i.e.  the pectoral fin, tail bud and 
pharyngeal neural crests. More importantly, treating this transgenic line with RA does not 
induce the reporter gene expression in the tailbud, pectoral fin and pharyngeal areas, suggesting 
that the RARγ/RXR complex may not have transcriptional activator role in zebrafish. 
Therefore, the effects caused by RARγ agonist treatment to zebrafish were very likely to be due 
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to disruptive effects on gene repressive activity, rather than transcriptional activation.  
However, it may not be completely concluded that the effects of RARγ agonist are solely driven 
through effects on the RAR/RXR, because RA can also trigger non-genomic effects by kinase 
cascade activation (Al Tanoury et al., 2013).  
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6.2. Specificity Issue 
The is an unresolved question in this project regarding the specificity of the RARγ 
agonist for zebrafish rarg. Although human and zebrafish RARs share similar homology (Hale 
et al., 2006; Waxman and Yelon 2007), the specifity of the RARγ agonist was proven in a 
mammalian cell line (Hughes et al., 2006). This means that the agonist may have the off-target 
affects in zebrafish cells. Moreover, zebrafish has two rarg isotypes, which are rarga and rargb 
(Waxman and Yelon 2007). Therefore, even if the agonist is specific for the receptor, it is 
important to know whether both receptors are responsive to the RARγ agonist or either of them.  
The simplest and easiest way to investigate the specificity of the RARγ agonist is the 
experiment in which the rarg receptors have been disrupted, followed by RARγ agonist 
treatment. Morpholino is a common method to block gene translation into protein, but the use 
of morpholino injections can trigger the p53 pathway and induce apoptosis, plus most 
morpholinos have toxic off-target effects (Bedell et al., 2011). Therefore, co-injection with p53-
morpholinos has become a common practice to prevent morpholino-induced apoptosis (Bedell 
et al., 2011). However, RA signalling itself is implicated in the apoptotic pathway (Noy 2010). 
Therefore, the experiment of using morpholino injections to block rarg expression, with co-
injection of p53 morpholinos, followed by a RARγ agonist treatment may not give a 
straightforward answer on specificity. In fact, morpholino alone injections for rar give a lethal 
phenotype, and co-injection with p53 morpholino does provide viable embryos (Linville et al., 
2009). However, morpholinos to rarga and rargb show loss of pharyngeal arches, pectoral fin 
outgrowth and defective caudal fin (Linville et al., 2009). Therefore, these morphants have 
tissue losses, which were supposed to be then be affected by RAR gamma agonism if such an 
experiment were to proceed. Hence, it is impossible to use rarg morpholinos to then examine 
RARγ agonist specificity.  
Another possible model for specificity testing is using mutant zebrafish lines, which 
carry mutations in rarg. Using forward genetics screening using ENU (N-ethyl N-nitrosourea), 
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the Sanger Institute has been developing the zebrafish library of mutant zebrafish lines for every 
single zebrafish gene (Dooley et al., 2013). The project has identified a mutant line of rarga. 
The mutation is a non-sense mutation and the detail can be found on the Sanger Institute 
website (http://www.sanger.ac.uk/sanger/Zebrafish_Zmpgene/ENSDARG00000034117). 
Therefore, this mutant zebrafish line is a useful candidate for examination of the RARγ agonist 
specificity. The mutant line is currently heterozygous. Phenotyping of the homozygous embryos 
is also an interesting study to compare with the morpholino-injected phenotype (Linville et al., 
2009). However, the current mutant line is in F1 stage and has not yet been released for 
investigation. 
An alternative method to random mutagenesis for forward screening mutagenesis is to 
use reverse genetics. TALENs (Tal effector nucleases) have become powerful tools for gene 
editing (Chen et al., 2013). These nucleases can bind to specific DNA sequences, induce double 
stranded DNA breaks, resulting in insertional and deletional mutations. The TALENs technique 
has been shown to be 10 times more mutagenic than ZFN (Zinc Finger Nucleases), but the 
efficiency of TALENs is negatively proportionate to the CpG islands percentage in the target 
DNA sequences (Chen et al., 2013). Therefore, the same efficiency of TALENs mutagenesis 
cannot be found in rarga and rargb because the amount of CpG island content in rarga and 
rargb may not be equal.  Using the free online CpG island finder software provided by 
University of Southern California, zebrafish rarga CpG islands in genomic DNA was 501bp 
out of 128483bp, but there was no CpG island in zebrafish rargb, suggesting higher success rate 
of TALEN mutagenesis can be achieved for rarga than rargb gene edits. 
The breakthrough discovery of bacterial acquired immune system has opened a new 
chapter of genomic engineering. After viral or bacterial challenge, most bacteria and archaea 
integrates the foreign DNA spacer fragments, then they produce cluster regulatory interspaced 
short palindromic repeats (CRISPR) driven by CRISPR associated system (CAS) to resist the 
phage challenge (Barrangou et al., 2007). This CRISPR mechanism causes double strand DNA 
breaks and it has been used as a powerful tool for genome editing for cell lines and model 
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organisms including zebrafish (Hisano et al., 2013). In zebrafish, it has been shown the genome 
editing produced by CRISPR and Cas9 system can also transmit to the germ lines with an 
efficiency as high as 100%, providing a good perspective of permanent mutant lines generation 
(Hwang et al., 2013). More interestingly, this technique can not only knock-out the expression 
of genes of interest in zebrafish, but also knock-in genes of desire at the same time by co-
injection (Chang et al., 2013). Therefore, using these target specific gene editing tools, not only 
can the RARγ agonist specificity problem can be solved, but also the whole new level of RA 
signalling study can be achieved.  
The specificity test can be achieved by targeted genome edition on ligand binding 
domains of zebrafish rarga and rargb. By doing so, the genomic DNA which encodes the exons 
containing the ligand binding domains of rarga or rargb will be removed by double strand 
break. Therefore, the ligands will no longer bind to the modified receptors which will still have 
the genomic DNA encoding DNA binding domains and co-repressor binding domains. Treating 
these rarga or rargb with RARγ agonist will not only provide the specificity of this agonist but 
will also show the possible non-genomic effects of agonist. In fact, this genome editing tools 
can also bring the other aspects of RA receptor function rather than specificity. By mutating the 
DNA sequence of rarga or rargb which encodes the DNA Binding Domain (DBD), the study 
will further explore the receptor’s involvement in its repressor role probably by mimicking the 
effects caused by rarga and rargb morpholinos injected embryos. Further studies can follow for 
the roles of co-repressor binding, RXR-binding and co-activator recruiting.   
Although the induced mutation techniques can improve the specificity of RARγ agonist 
on zebrafish rarg, these techniques can still not prove the actual interaction between the ligand 
and the receptor complex. Therefore, immuno-precipitation method can provide the important 
ligand-receptor interaction information. If the ligand (RA) binds to the rarg and causes the 
transcriptional activation, the immuno-precipitation results should be able to show the 
difference between the receptor-complex composition before the RARγ agonist treatment and 
after treatment. For example, the receptor complex retrieved from rarg expressing tissues 
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before treatment should show the protein complex of rarg/rxr and co-repressor. However, the 
protein complex should show rarg/rxr and co-activator (probably other transcriptional activation 
protein complex) in the immuno-precipitation after the treatment if the RARγ agonist is 
involved in transcriptional activation.  
Another interesting technique for specificity is to visualize the interaction between the 
ligand and the receptor using GEPRAs (Genetically Encoded Probes for RA). The technique 
uses the modified version of RAR which is tagged with GFP and YFP. In ligand free stage, the 
receptor emits the green colour and the yellow colour is emitted when the ligand is bound to the 
receptor. This is the protocol used for visualization of intrinsic RA in zebrafish which is already 
published (Shimozono et al., 2013). Therefore, using the genetically modified rarga and rargb 
tagged with GFP and YFP transgenic lines may provide the evidence for interaction between 
the RARγ agonist and the receptor.  
Another important question in this project is whether rarga and rargb are 
transcriptionally activated by RARγ agonist. The canonical RA signalling involves ligand 
binding to the receptor, RAR/RXRhetero dimer and RARE (Linney et al., n.d.). Therefore, 
using the transgenic line which has RARE:YFP transgenic zebrafish (Perz-Edwards et al., 
2001) can provide the crucial information transcriptional activation.  
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6.3. Conclusion 
Treatment of zebrafish embryos with a RARγ agonist showed disruptive effects on 
normal development because the rarga and rargb were presumably needed in generepressor 
roles rather than in a transcriptional activator role. Treating with RARγ agonist may have 
disrupted the rarg repressor functions which are needed for normal development. The results 
suggested zebrafish either rarga or rargb or both may have important roles in stem/progenitor 
cells. 
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